Glaucoma, Vision & Longevity: Supplements & Science

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/color-and-contrast-specific-perimetry-to-probe-retinal-ganglion-cell-subtype-vulnerabilityTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Introduction Vision relies on many kinds of retinal ganglion cells (RGCs), each tuned to different color or contrast signals. Standard visual field tests use white-on-white (achromatic) stimuli and measure overall sensitivity, but early or selective damage in diseases like glaucoma can hide behind normal full-field results. Specialized perimetry tests now probe specific pathways by using color or temporal contrast stimuli. For example, blue-on-yellow perimetry (Short-Wavelength Automated Perimetry, SWAP) presents a bright blue target on a yellow background to isolate the short-wavelength (blue) cone pathway and its small bistratified RGCs (). Similarly, red–green (chromatic) tests aim at the long-/medium-wavelength cone pathways (parvocellular system), and flicker/temporal tests (like frequency-doubling perimetry or high-frequency flicker) stress the large parasol (magnocellular) RGCs. By dissecting vision in this way, clinicians hope to catch damage in specific RGC subtypes earlier or more precisely than with white-on-white testing. This article reviews these color- and contrast-specific perimetry methods and how they relate to glaucoma and optic nerve disease. We discuss what blue-yellow and red-green perimetry can reveal about pathway dysfunction, how flicker perimetry examines temporal contrast processing, and how these functional losses map onto structural imaging (OCT) and blood flow metrics (OCT-Angiography). We also consider evidence on whether such targeted tests predict later decline on standard fields, and suggest practical testing protocols that maximize diagnostic insight without overly straining patients. Color- and Contrast-Specific Perimetry Blue–Yellow (SWAP) Perimetry Blue-on-yellow perimetry (SWAP) is a well-known color test. It uses a large, narrowband blue stimulus (around 440 nm) presented on a bright yellow background (). The high-luminance yellow field adapts the red and green cones so that the remaining pathway – the short-wavelength (blue) cones and their small bistratified RGCs – respond mainly. In effect, SWAP “isolates” the blue-cone channel. Early glaucoma often affects these small bistratified cells, so SWAP can reveal field loss sooner than conventional testing (). Indeed, studies report SWAP can detect visual field defects in glaucoma suspects or early glaucoma eyes before standard perimetry shows losses, suggesting higher sensitivity for early damage () (). For example, one study found SWAP deficits strongly correlated with retinal nerve fiber thinning (r≈0.56 in the inferior quadrant) in glaucoma patients (), indicating SWAP loss matches structural damage. However, SWAP has practical limitations. It is sensitive to lens opacity (cataracts make results unreliable) and generally requires longer testing (to overcome adaptation effects). Clinically, SWAP often uses a “SITA-SWAP” algorithm to shorten time, but patients may still fatigue easily. In research, SWAP fields have shown greater mean deficits than white-on-white fields in glaucoma suspects () (), but reproducibility can be an issue. Another SWAP-based approach measures pupil responses (pupillography) to blue vs yellow stimuli, reflecting melanopsin ganglion cell function. One study found blueSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/inequities-in-access-to-visual-field-testing-and-their-outcome-consequencesTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Inequities in Access to Visual Field Testing and Their Consequences Visual field testing (also called perimetry) is a key tool eye doctors use to catch vision-threatening diseases like glaucoma early. In glaucoma, for example, people usually feel no symptoms until serious vision loss has occurred, so doctors rely on tests to measure the full field of a person’s vision (). Routine visual field tests help detect early damage to the optic nerve before it causes blindness. However, not everyone has equal access to these tests. In many parts of the country, people – especially those in rural areas or with low income – face barriers to getting regular eye exams and visual field tests. This article maps out how geography and socioeconomic factors affect who gets tested, how late disease is caught, and what can be done to close these gaps. Uneven Access Across Communities Geographic Barriers Living far from an eye clinic can make testing hard. A recent large study found glaucoma patients in isolated rural areas were far less likely to get the recommended follow-up eye exams than those in cities (). In fact, rural patients’ odds of receiving a needed optic nerve evaluation were 56% lower than urban patients (). Similarly, research of insured patients across the U.S. found wide variation by community in whether newly diagnosed glaucoma patients get any visual field test: in some places as few as 51% got tested within two years of diagnosis, while in others 95% did (). Some communities had over 25% of new glaucoma patients receive no visual field testing at all in the first two years after diagnosis (). These findings show that where a person lives – and the resources of that community – can make a big difference in whether they get basic vision testing. Socioeconomic and Insurance Factors Money matters too. Patients with lower income or without good insurance often get tested less. For example, one study showed that people on Medicaid (public insurance for low-income individuals) with glaucoma were much less likely to get visual field tests compared to patients with commercial insurance (). Only about 35% of Medicaid patients received a visual field test within 15 months of diagnosis, versus 63% of privately insured patients (). This means Medicaid patients were over three times as likely to get no glaucoma testing at all after diagnosis (). Because Medicaid patients are disproportionately low-income and include many racial minorities, these insurance disparities contribute greatly to unequal care. Racial and Ethnic Disparities Race and ethnicity intersect with income and location. Studies have found that Black, Hispanic, and Asian patients with glaucoma often receive fewer visual field tests than White patients, even after accounting for age and severity () (). For instance, Black and Asian glaucoma patients in one clinic-based study underwent about 3–5% fewer tests per visit than White patients, despite having more advanced disease at baseline (). Another analysis showed Black patients had a 17% lower chance of getting the recommended optic nerve exams than White patients, and Hispanic patients also lagged in follow-up visits (). These differences may reflect factors like lower insurance coverage, less access to Support the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/low-carb-diets-and-nocturnal-blood-pressure-dips-ocular-perfusion-risks-and-benefitsTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Introduction Low-carbohydrate diets (such as ketogenic diets) have become popular for weight loss and blood sugar control. These diets can significantly improve metabolic health by lowering insulin, blood sugar, and even blood pressure () (). But for people with eye disease like glaucoma – especially the normal-tension type (NTG) – it is important to consider how major changes in diet and body chemistry might affect blood pressure patterns. In particular, doctors are paying attention to nocturnal hypotension (excessive night-time blood pressure drops) because the optic nerve is sensitive to low perfusion. Here we examine whether cutting carbs could alter the normal day-night blood pressure cycle and eye blood flow, and how to monitor these circadian changes safely. We will also weigh the potential benefits of better metabolic control against the risks of too-low blood pressure at night. Throughout, we rely on evidence from clinical studies and expert reviews () (). Low-Carbohydrate Diets and Blood Pressure Low-carb diets (for example, very-low-calorie or “keto” diets) can improve metabolic markers. They often lead to weight loss, better blood sugar control, and reduced insulin levels (). Multiple studies have found that switching to a low-carbohydrate diet tends to lower blood pressure as well. For instance, in a trial of overweight adults with high blood sugar, a very-low-carb diet lowered systolic blood pressure by nearly 10 mmHg on average over four months – a greater drop than with a standard DASH-style diet (). This effect is likely partly due to losing water weight and salt (since low-carb diets can cause an initial diuresis) and partly due to overall improved cardiovascular health. In fact, one review notes that keto-style diets are specifically recommended by diabetes experts because they improve blood pressure as well as glycemic control (). However, lowering blood pressure quickly can have side effects. When people start a ketogenic diet, many report what is colloquially called the “keto flu”: headaches, lightheadedness, and fatigue (). These symptoms are thought to come from temporary fluid and electrolyte shifts (for example, losing more sodium and dropping blood pressure). In practice, this means that some people on a strict low-carb diet may feel dizzy or unusually tired, especially in the first weeks. For patients already on blood-pressure medications, this added effect can increase the chance of excessive hypotension (too-low blood pressure), especially at night. In summary, low-carb diets often improve blood pressure long-term () (), but they can cause acute dips that should be monitored, especially in sensitive individuals. Nighttime Blood Pressure Dips and Eye Health Our blood pressure normally follows a day-night pattern: it dips during sleep and rises by morning. For most healthy people, night-time blood pressure falls by about 10–20% from daytime levels. This “nocturnal dip” is part of normal physiology. But exaggerated nocturnal dipping (for example, a drop much greater than 10–20%) can be risky for the eyes. The reason is ocular perfusion: the optic nerve and retina need a constant flow of blood. Ocular perfusion pressure (OPP) is roughly tSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/macronutrient-patterns-and-intraocular-pressure-a-systematic-evaluationTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Diet and Eye Pressure: How Proteins, Fats, and Carbs May Affect Glaucoma Glaucoma is a leading cause of irreversible vision loss, usually caused by damage to the optic nerve often driven by high intraocular pressure (IOP) – the fluid pressure inside the eye. Lowering IOP is the main way to treat glaucoma, but eye pressure can be influenced by more than just medications. Recent research suggests that what we eat – especially the balance of proteins, fats and carbohydrates – may play a role in eye pressure and glaucoma health () (). In particular, certain dietary patterns (for example, low-carb or Mediterranean-type diets) have been linked to glaucoma risk and measures like nerve-fiber thickness and visual field loss. At the same time, scientists have begun to uncover biological pathways – from blood sugar and osmotic pressure to insulin effects and lipid signaling – that could explain how diet affects eye fluids and drainage. This article reviews the latest evidence on macronutrient patterns and glaucoma. We will survey epidemiologic studies of diet patterns (low-carbohydrate, low-fat, high-protein and Mediterranean-style diets) in relation to glaucoma, nerve thickness (the retinal nerve fiber layer), and vision loss. We will also explain possible mechanisms – including osmotic shifts from sugar, insulin’s effects on eye fluid, and the role of fats and lipid signals in the eye’s drainage mesh – that might link diet to IOP. Finally, we highlight gaps in the research (notably the lack of long-term trials) and suggest ways future studies can standardize diet tracking and glaucoma measures to get clearer answers. Dietary Patterns and Glaucoma: What the Studies Show Low-Carbohydrate Diets The idea of a low-carbohydrate diet (shifting calories from carbs to more protein and fat) has been widely studied for weight loss and diabetes, but does it affect glaucoma? A large U.S. study examined over 185,000 adults over decades and tracked their diets and glaucoma outcomes. That study found no overall link between long-term low-carb eating and the risk of primary open-angle glaucoma (). In other words, simply eating a low-carb or ketogenic-style diet did not clearly reduce (or increase) glaucoma risk in most people (). However, this same research did find an intriguing hint: if people substituted more vegetable-based fats and proteins (like plant oils, nuts, or beans) for carbohydrates, they tended to have a lower risk of a specific glaucoma pattern (one that affects central vision early) () (). In practical terms, swapping plants and healthy fats for carbs might modestly protect against one subtype of glaucoma () (). In contrast, sugary or high-glycemic carbohydrates seem to raise eye pressure acutely. For example, one Taiwanese health study measured people’s blood sugar two hours after a standard meal and compared it to eye pressure. They found that participants with higher post-meal blood glucose levels had significantly higher IOP – by several millimeters of mercury – than those with lower glucose (). Each rising quartile of after-meal sugar gave a clear trend of higher eye pressure (). This suggests that spikes in blood sugar (which happen with high-carb meals) can temporarily increase IOP. In fact, classic stuSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/personalized-nutrition-in-glaucoma-nutrigenomic-interactions-with-macronutrient-metabolismTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Introduction Glaucoma is a group of eye diseases that damage the optic nerve and can lead to vision loss if not treated. High intraocular pressure (IOP) – the fluid pressure inside the eye – is a major risk factor for glaucoma. Standard treatments (like eye drops and surgery) focus on lowering IOP. But growing research suggests that diet and nutrition may influence glaucoma risk and progression () (). For example, diets rich in vegetables (sources of nitric oxide/nitrates) have been linked to lower glaucoma risk () (). Personalized nutrition (or precision nutrition) is the idea of tailoring a person’s diet to their unique biology, including their genes and metabolism. The new field of nutrigenomics studies how genetic differences affect the way our bodies process nutrients (like fats and carbohydrates) and how these interactions impact health. In glaucoma, nutrigenomics could one day help us recommend the best balance of fats, carbohydrates, and proteins for each patient, based on their genes. This article explores how key genes involved in fat and carbohydrate metabolism (notably APOE, PPAR family genes, FADS, and NOS3) might guide personalized diets for glaucoma; how clinical trials could test such approaches; and what ethical and practical issues arise. Genes and Macronutrient Metabolism Certain genes play major roles in determining how our bodies handle fats and carbohydrates. Variants (different versions) of these genes can change metabolic pathways. In the context of glaucoma, several genes are of interest: APOE (Apolipoprotein E) – This gene makes a protein that transports cholesterol and fats in the body, especially in the brain and retina (). There are three common APOE variants (called ε2, ε3, ε4). People with the ε4 version tend to have higher blood cholesterol levels. In general nutrition science, APOE4 carriers often show larger cholesterol changes when they change their intake of saturated fats (). (For example, cutting saturated fat often lowers cholesterol more in APOE4 individuals than in others.) In glaucoma research, some studies even suggest APOE4 might protect the optic nerve from damage (), though the picture is complex. From a diet viewpoint, an APOE4 carrier might benefit especially from a low saturated-fat diet and increased healthy fats (in line with heart-healthy guidelines). PPARs (Peroxisome Proliferator-Activated Receptors) – These genes (especially PPARα and PPARγ) are regulators that turn on or off pathways controlling fat and sugar metabolism. The PPARγ gene has a well-studied variant called Pro12Ala. People carrying the “Ala12” variant often have greater sensitivity to different types of fat in the diet. For instance, one trial found that carriers of PPARγ Ala12 lowered their cholesterol and triglyceride levels more when their diet had a higher ratio of unsaturated fats (polyunsaturated/saturated fat) (). Another study showed that Ala12 carriers lost more weight on a Mediterranean-style diet rich in olive oil (a monounsaturated fat) than on a standard low-fat diet (). In short, PPAR variants influence how well someone responds to healthy (unsaturated) versus less healthy fats. For glaucoma patients with these PPAR variants, emphasizing omSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/medium-chain-triglycerides-vs-long-chain-fats-rapid-ketosis-and-visual-functionTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Medium-Chain Triglycerides vs Long-Chain Fats: Rapid Ketosis and Visual Function Medium-chain triglycerides (MCTs) are fats with shorter carbon chains (mostly 8–12 carbons, like caprylic and capric acid) that are found naturally in coconut oil and breast milk. Long-chain fats (LCTs) include most other dietary fats (14+ carbons) such as olive or sunflower oil. The body handles them differently: MCTs go straight to the liver through the bloodstream and are rapidly turned into ketones (an alternative fuel), whereas LCTs enter via the gut’s lymph system and take longer to process. In one study, giving healthy adults pure C8 MCT oil caused blood ketone levels to jump roughly four times higher than the same calories of coconut oil^ (). In short, MCTs raise ketones much faster than LCTs. (Ketones are molecules the liver makes from fat that many cells – including brain and retina cells – can burn for energy when glucose is low.) MCTs have been studied for brain and eye health. In ageing and certain eye diseases, glucose uptake can drop and cells starve for fuel. For example, low brain glucose use in Alzheimer’s or ageing has led researchers to try ketone supplements to “bypass” this energy problem. One conclusion from a clinical trial was that optimizing MCT formulas might help counteract declining brain glucose use in aging (). In other words, ketones from MCT could provide extra energy when sugar isn’t enough. Similarly, these extra ketones may help visual processing and cognition when given acutely. In experiments, healthy adults who drank MCT oil (versus the same amount of olive oil) performed better on certain mental tasks – for example, one dose of MCT improved attention and decision-making in a Stroop-type test (). (Working memory also improved after 4 weeks of daily MCT compared to long-chain oil ().) These findings suggest that MCT-derived ketones can give the brain and eyes an energy boost, potentially speeding up cognitive-visual tasks. Importantly, glaucoma – a common disease of the optic nerve – involves energy failure in the retinal ganglion cells (RGCs) that carry vision signals. Research shows glaucoma is tied to metabolic and mitochondrial dysfunction (). RGCs are very active nerve cells with many mitochondria located near the optic nerve head (). They rely heavily on oxygen-based metabolism for ATP energy, so if mitochondria struggle (as can happen in glaucoma), RGCs get damaged. Because ketones can feed mitochondria, scientists are exploring if a ketogenic approach can help. Animal studies support this idea: In a mouse model of chronic glaucoma, feeding an 8-week ketogenic (very low-carb, high-fat) diet protected the RGCs and their axons. The ketogenic mice had more retinal mitochondria and better energy status and far fewer RGCs died, compared to control mice on a regular diet (). That study actually showed ketogenic diet “generated mitochondria, improved energy availability, … [and] protected RGCs” in the optic nerve (). Another recent glaucoma study found that ketones helped clear out damaged mitochondria (via mitophagy) in RGCs under stress, further protecting these cells (). How might ketones reach the nerves? In the optic nerve head, astrocytes (support cells) wrap arouSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/protein-intake-homocysteine-and-pseudoexfoliation-glaucoma-riskTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Introduction Pseudoexfoliation syndrome (PEX) is an age-related eye condition characterized by the accumulation of flaky, white fibrillar material on structures in the front part of the eye (such as the lens capsule and pupillary border) () (). This material is rich in elastic microfibrils and other extracellular matrix proteins, so PEX is often described as an elastosis – essentially an overproduction of elastic fiber components in the eye () (). Over time, PEX can cause elevated eye pressure and trigger a form of glaucoma (called pseudoexfoliation glaucoma) that damages the optic nerve and can lead to vision loss if untreated. Patients with PEX also appear to have higher rates of vascular diseases (for instance, stroke or heart disease), suggesting systemic factors may be involved. Scientists have noted that patients with PEX glaucoma often have higher blood levels of the amino acid homocysteine than people without the disease. Homocysteine is a byproduct of normal protein metabolism – it comes from the essential amino acid methionine. Diets very high in protein (especially animal protein) can deliver a lot of methionine. If the body cannot fully convert homocysteine back into other useful compounds, homocysteine can accumulate in the blood. In this article, we explore how high-protein diets and one-carbon metabolism (which depends on B vitamins like folate and B12) might influence homocysteine levels and thus potentially affect the risk of developing pseudoexfoliation glaucoma. We will also discuss how abnormal homocysteine might disrupt enzymes involved in building and remodeling the eye’s connective tissue (notably LOXL1, a lysyl oxidase enzyme that cross-links elastin fibers) () (). Finally, we suggest how future studies could be designed to test these links using detailed dietary data, genetic testing, blood biomarkers, and advanced eye imaging. Protein Intake, Methionine, and Homocysteine When you eat protein, your body breaks it down into amino acids – the building blocks of proteins. One amino acid, methionine, is found abundantly in many proteins (especially in red meat, eggs, and dairy). Methionine is converted in the body to homocysteine. Normally, homocysteine is then either recycled back into methionine or converted into cysteine, and this process depends heavily on B vitamins – folate (vitamin B9), vitamin B12, and vitamin B6. If these vitamins are insufficient, or if dietary methionine is very high, blood homocysteine levels can rise. Controlled diet studies in healthy volunteers show exactly this relationship: an 8-day high-protein diet (about 21% of energy from protein, versus only 9% in a low-protein diet) led to significantly higher post-meal homocysteine levels throughout the day, even though fasting homocysteine didn’t change much () (). In other words, after people ate protein-rich meals, their plasma homocysteine spiked higher than it did when they ate low-protein meals () (). The researchers noted that “a high protein intake and hence a high intake of methionine—the sole dietary precursor of homocysteine—may raise plasma tHcy concentrations” (). In practical terms, this means diets very rich in meat, fish, eggs, or other high-methionine foods can transiently increase homocysteine unless balanced bySupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/mtor-autophagy-modulation-by-amino-acids-in-rgc-degenerationTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Nutrient Sensing and RGC Survival in Glaucoma Glaucoma is a major cause of irreversible blindness worldwide, involving damage and loss of the eye’s retinal ganglion cells (RGCs) and their axons. These cells send visual signals from the eye to the brain, so their health is vital for vision. Current glaucoma treatments lower eye pressure, but many patients still lose vision, highlighting the need for neuroprotective strategies that directly support RGCs () (). Emerging research shows that how RGCs sense and use nutrients (like amino acids) can influence their survival under stress. In particular, the mechanistic target of rapamycin (mTOR) pathway and autophagy – a cell’s recycling program – play key roles in RGC health. This article explores how amino acids (especially leucine, a building-block of protein) affect mTOR and autophagy in RGCs under glaucomatous stress, and how we might test dietary interventions to help protect vision. We also discuss how to measure both structural (OCT imaging) and functional (PERG, VEP) outcomes alongside blood/CSF biomarkers of nutrient signaling, and consider the balance between growth signals and protein cleanup in cells. mTOR and Autophagy: Balancing Growth vs. Cleanup Cells constantly balance between building up structures and recycling damaged parts. mTOR is a Master growth sensor: when nutrients are abundant, mTOR turns on protein production and cell growth () (). Under those conditions, mTOR suppresses autophagy (the cell’s ”recycling bin” that breaks down damaged components) (). In contrast, when nutrients or energy are low (or stress is high), mTOR activity falls and autophagy is activated, helping cells survive by cleaning up waste and providing raw materials for energy. In healthy neurons, a basal level of autophagy is important to remove misfolded proteins and worn-out mitochondria () (). RGCs are especially vulnerable to damage because they are long-lived nerve cells that cannot dilute waste by dividing. Studies show that autophagy protects RGCs under stress. For example, one landmark study found that blocking mTOR with the drug rapamycin (which boosts autophagy) helped RGCs survive after optic nerve injury (). In glaucoma models, enhancing autophagy was generally neuroprotective. As Boya and colleagues explain, stressed RGCs use autophagy to reduce oxidative damage and recycle nutrients, which can prolong cell survival () (). In short, keeping autophagy active helps RGCs stay healthy, especially under the chronic stress of glaucoma. However, too much autophagy or mis-timed autophagy can also be harmful, so the balance is delicate (). Excessive mTOR inhibition (over-activating autophagy) could have broad effects. The interplay between mTOR and autophagy in RGCs is complex. For example, shutting off mTOR can reduce protein synthesis needed for repair, while hyperactive mTOR (from too many nutrients) can starve the recycling system. This balance must be managed carefully in any intervention. Leucine and Amino Acid Signaling Amino acids are not just building blocks of proteins; they are also key regulators of cell metabolism. Leucine is one of the three branched-chain amino acids (BCAAs), along with isoleucine and valine. Leucine is a potent activator of mTORC1 (the nutrient-sensing complex of mTOR)Support the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/nr-vs-nmn-vs-nicotinamide-for-glaucoma-which-nad-booster-has-the-strongest-evidenceTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:NAD+ and Glaucoma: Why Vitamin B₃ Matters Glaucoma is an aging-related eye disease in which retinal ganglion cells (RGCs) – the nerve cells that carry visual signals from the eye to the brain – gradually die off. Pressure-lowering treatments (drops, lasers, surgery) are the standard of care, but many patients still experience slow vision loss. Researchers have therefore been exploring additional neuroprotection strategies. One promising idea is boosting NAD+ (nicotinamide adenine dinucleotide) – a vital cell energy molecule – because NAD+ levels naturally decline with age (). Lower NAD+ may leave RGCs less able to meet their high energy needs, especially under glaucoma stress. In fact, one lab review notes that “glaucoma is a neurodegenerative disease in which neuronal levels of NAD decline,” and shows that nicotinamide (vitamin B₃) can protect RGCs in multiple animal glaucoma models (). This finding has inspired human trials of NAD-boosting supplements in glaucoma. Current research has focused on three NAD precursors: nicotinamide (vitamin B₃), nicotinamide riboside (NR), and nicotinamide mononucleotide (NMN). All three are natural forms of B₃ that feed into the NAD+ salvage pathway (). Nicotinamide (often called niacinamide) is a form of vitamin B₃ found in foods and multivitamins; NR and NMN are specialized NAD precursors found in small amounts in some foods (and sold as supplements). But do they really help glaucoma? Below we compare what is known about each one in plain language. All claims below are backed by recent science and trials. Nicotinamide for Glaucoma Why is nicotinamide being studied? Researchers study nicotinamide because it directly boosts NAD+ via the cell’s salvage pathway and has strong lab evidence in glaucoma models. In aging cells, NAD+ “declines with age at a systemic level” (). RGCs are very energy-hungry cells in a high-stress environment (high pressure can damage mitochondria inside them). Boosting NAD+ could supercharge RGC metabolism and help them survive. In rodent glaucoma experiments, high-dose nicotinamide dramatically protected RGC bodies and axons. For example, Tribble et al. (2021) report that dietary nicotinamide blocked the early metabolic disruptions caused by high eye pressure and improved mitochondrial function in rat retinas (). In simple terms, vitamin B₃ helped the energy cells in the retina keep working properly under stress. This strong preclinical data has given researchers confidence to try nicotinamide in human glaucoma. Human trial evidence for nicotinamide Human studies are still small but encouraging. A 2022 trial in open-angle glaucoma (with moderate field loss) gave patients high-dose nicotinamide plus another agent (pyruvate). Participants took 1–3 grams of nicotinamide daily. Over ~2 months, the treatment group showed significantly more improvement in visual field test points than placebo did (). Specifically, the median number of improved field locations was 15 in the nicotinamide group versus 7 in placebo (p=0.005) (). Secondary measures of field sensitivity also tended to improve more with treatment. Although this triSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/how-useful-is-oct-at-each-stage-of-glaucomaTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Introduction Glaucoma is a progressive eye disease where the optic nerve at the back of the eye is damaged, leading to vision loss. Because glaucoma often causes no symptoms until later, doctors use various tests to spot it early and track it. One key tool is Optical Coherence Tomography (OCT). OCT is a non-invasive imaging scan that uses light to make cross-section pictures of the retina (the light-sensing layer of the eye). It can measure the thickness of important retinal layers and the optic nerve head. By tracking these measurements over time, OCT helps doctors see damage to nerve fibers before it shows up on vision tests. However, OCT is not perfect or standalone – it’s one piece of the puzzle in glaucoma care () (). What OCT Measures and How to Read It OCT produces detailed images of the retina, which doctors interpret in simple ways. The main things OCT measures are: Retinal Nerve Fiber Layer (RNFL) Thickness: This is the layer of nerve “wiring” that runs from the retina into the optic nerve. Glaucoma causes this layer to thin over time. OCT scans circle the optic nerve and report the RNFL thickness (often as average thickness and in each quadrant). Thinner-than-normal RNFL can indicate glaucoma damage (). Ganglion Cell Complex (GCC): This is the layer in the macula (central retina) that contains the cell bodies of the retinal ganglion cells (the nerves that carry vision signals to the brain). Since glaucoma kills these cells, doctors also measure the macula’s GCC thickness. OCT can show if these cells (and their inner synapse layer) are thinning. Optic Nerve Head Structure: OCT can image the back of the eye (the optic disc) directly. It measures features like the “cup” and “disc” sizes (with metrics such as the rim area). A large cup or small rim can be a sign of glaucoma. However, OCT’s advantage is mostly its precise thickness measures, not just the cup/disc ratio. Macular (Central Retina) Thickness: Beyond the ganglion cell layer, OCT measures overall macular thickness. Some devices show color maps of the macula. Thinning in parts of the macula may also hint at glaucoma. Progression Over Time: Critically, OCT allows comparison of scans over months and years. The software can flag statistically significant thinning from one visit to the next. For example, a drop of ~4–5 microns in average RNFL over a year can suggest real progression (). Doctors often use “guided progression” tools in OCT to see if areas are getting thinner faster than normal aging. Each OCT result comes with color-coded maps and numbers. Green usually means “within normal limits,” yellow means “borderline,” and red indicates “outside normal limits” (thin) compared to a database of healthy eyes of the same age. Importantly, these colors are just estimates. A “red” area says that part of your retina is thinner than 95% of healthy eyes. It does not by itself confirm glaucoma – it simply flags an unusual finding (). Overall, OCT gives doctors precise physical data—how thick or thin the nerve layers are. These numbers let doctors track change more objectively than subjective exams. OCT in Suspected (Pre-Glaucoma) Conditions Even before glaucoma is officially diagnosed, OCT can be very helpful. This is often called “preperimetric” glaucoma – where the optic nerve loSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/new-glaucoma-treatments-in-2026-what-patients-should-know-about-longer-lasting-eye-pressure-controlTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:New Glaucoma Treatments for 2026: Longer-Lasting Pressure Control Glaucoma, a leading cause of vision loss, is driven by high intraocular pressure (IOP) in the eye. Daily eye drops are the main treatment, but many patients find them hard to use consistently. Drops can sting, cause redness, or simply be forgotten in the busy routines of life () (). Missing doses can let eye pressure creep up, risking vision loss. Sustained-release glaucoma treatments aim to solve this by steadily delivering medication without daily drops. Instead of an eyedrop bottle, a doctor places a tiny implant or device that continuously releases glaucoma medicine for months. These approaches remove the need to remember daily drops and help keep pressure controlled around the clock () (). Below we explain how these new treatments work, who might benefit, and how they compare to traditional drops. We focus on the options most talked about for 2026, separating those already FDA-approved from those still being studied. How Sustained-Release Treatments Work Traditional glaucoma drops deliver medication onto the eye surface, but much of it washes away before it can work. Sustained-release devices sit inside the eye or on eye tissue and let out drug slowly over time. For example, Durysta is a tiny biodegradable rod (about 1.1 mm long) that an eye doctor injects into the anterior chamber (the front part of the eye) (). It contains 10 micrograms of bimatoprost (the medicine in Lumigan drops) embedded in a dissolving polymer. Once placed, Durysta releases bimatoprost steadily for about 4–6 months () (). The implant then dissolves on its own, so no second procedure is needed. Another approach, used by iDose TR, is a tiny titanium implant anchored into the eye wall. This anchoring device contains a reservoir of travoprost (another prostaglandin drug). About 75 micrograms of travoprost continuously elutes (seeps out) into the eye through a controlled membrane (). The iDose TR device stays in place for up to 2–3 years, delivering medication 24/7. (As of early 2026, the FDA has even approved re-administering iDose TR when the first dose runs out () ().) Both Durysta and iDose TR release prostaglandin-type drugs that help fluid drain out of the eye, lowering pressure. Similarly, experimental implants like OTX-TIC (Paxtrava), PA5108, and ENV515 are designed as tiny biodegradable implants or particles that doctors insert into the eye. They work the same way: a drug (e.g. travoprost or latanoprost) is slowly released over months () (). Punctal plugs, by contrast, sit in the tear drainage ducts (near the nose) and gently release medication into the tears () (). Each system steadily bathes the eye in medicine, nearly eliminating the peaks and troughs of pressure seen with once-daily drops. Who might benefit? These devices are best for people with open-angle glaucoma or ocular hypertension who need regular IOP control but struggle with daily drops. Older patients, those with limited mobility or trouble handling eye drops, or anyone who miss doses are prime candidates () (). Because the drugs are in continuous contact with the eye, these devices often work as well as or better than drops while leavSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/endothelin-1-peptide-and-glaucoma-targeting-a-problem-pathwayTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Endothelin-1 Peptide and Glaucoma: Targeting a Problem Pathway Glaucoma is an eye disease in which the optic nerve is damaged, often by high pressure inside the eye. Standard treatment focuses on lowering intraocular pressure (IOP). However, doctors increasingly recognize that poor blood flow and other factors also contribute to nerve damage. One molecule under study is endothelin-1 (ET-1). ET-1 is a natural peptide (small protein) made by blood vessel cells and eye tissues that is the most potent vasoconstrictor in the body (). In other words, it strongly narrows blood vessels. When ET-1 levels are high, retinal and optic nerve blood vessels can tighten, reducing oxygen and nutrients to the optic nerve. In this way, too much ET-1 may “stress” the optic nerve fibers and contribute to glaucoma damage (). In fact, many studies find ET-1 is elevated in glaucoma patients’ blood and eye fluid () (). Here we explain what ET-1 does in the eye, summarize the evidence linking ET-1 to glaucoma damage, and discuss possible treatments that block its pathway (rather than using ET-1 itself as a drug). What is Endothelin-1 and How Does It Affect the Eye? Endothelin-1 (ET-1) is made by cells lining blood vessels throughout the body, and it helps regulate normal blood pressure and flow. In the eye, ET-1 is produced in several places: the retina, the blood vessels of the eye, the retinal pigment epithelium, the optic nerve head, and the structures that make and drain fluid (aqueous humor) (). Under normal conditions, ET-1 keeps a balance: it tightens vessels when needed and releases them when other signals come in. However, ET-1 is a very powerful constrictor. Rosenthal and Fromm describe ET-1 as “the most potent vasoactive peptide known to date” (), meaning none of the body’s chemicals narrows vessels more strongly. In the eye’s tiny blood vessels, overactive ET-1 can seriously reduce blood flow. For example, if ET-1 rises, it causes vasoconstriction (narrowing) of blood vessels in the retina and optic nerve head (). This can trigger ischemia (low blood supply) in the optic nerve. Over time, that lack of oxygen and nutrients can injure or kill the retinal ganglion cells (the nerve cells in the retina whose fibers form the optic nerve). Rosenthal et al. note that such ischemia “is assumed to contribute to the degeneration of retinal ganglion cells” in glaucoma (). ET-1 also affects fluid drainage in the eye. Aqueous humor (the fluid in the eye) normally drains out through a spongy tissue called the trabecular meshwork. ET-1 makes those meshwork cells contract (), which can reduce outflow and potentially raise eye pressure. Indeed, Rosenthal’s review suggests that inhibiting ET-1 can lower IOP and protect nerves (), although not all studies agree on ET-1’s pressure effects. In summary, too much ET-1 can both increase eye pressure slightly and pinch the eye’s blood supply, creating a “double hit” to the optic nerve. Evidence Linking ET-1 to Glaucoma Damage Many clinical studies find that ET-1 levels are higher in glaucoma. For example, a recent meta-analysis pooled data from over 1,000 glaucoma patients and healthy people. It found that plasma ET-1 was significantly higher in patients with primary open-angle, normal-tension, and anglSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/substance-p-pain-and-neuroinflammation-in-glaucomaTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Substance P, Pain, and Neuroinflammation in Glaucoma Glaucoma is a chronic eye disease that damages the optic nerve and can lead to vision loss. Many people with glaucoma also suffer from ocular surface discomfort – redness, burning, or dryness of the eye – especially if they use eye drops or have surgery. These symptoms are not only uncomfortable, but they can make it harder to stick to glaucoma treatment. Researchers have discovered that Substance P – a small protein (neuropeptide) released by nerve endings – plays a key role in eye pain and inflammation. Understanding how Substance P works may help us treat these symptoms. This article explains Substance P’s role in eye inflammation and pain, why that matters for glaucoma patients, and what studies tell us about drugs that block this pathway. Importantly, we distinguish easing symptoms (like dryness or pain relief) from protecting vision (slowing the nerve damage in glaucoma). Substance P and Neuroinflammation Substance P (SP) is a signaling molecule made by nerve cells. When nerves are irritated or injured, they release Substance P into the surrounding tissue. Substance P then binds to its receptor (called the neurokinin-1 receptor, or NK1R) on nearby cells. This triggers several effects: blood vessels in the tissue expand and become leaky, immune cells (like white blood cells) are recruited, and inflammatory chemicals (cytokines) are released (). In simple terms, Substance P tells the body, “Something’s wrong here – send help!” This process is called neurogenic inflammation. It helps fight infection or heal damage, but it also causes redness, swelling, and pain. For example, in the cornea (the clear front of the eye), Substance P causes blood vessels to dilate and immune cells to come in (). It also directly amplifies pain signals by acting on nerve fibers (Aδ and C fibers) that carry pain to the brain (). Because the cornea is one of the most heavily-innervated tissues in the body, it can produce and respond to a lot of Substance P () (). Normally, a small amount of SP helps regulate tear production and blink reflexes (). But after injury or chronic irritation (such as allergic or dry eye), SP levels can surge. High SP can make the cornea and conjunctiva (the white part of the eye) much more sensitive and inflamed. In experiments, blocking SP’s action strongly reduces inflammation: nerves that lack the SP receptor show fewer immune cells arrive, and mice missing SP themselves have less swelling () (). In other words, Substance P turns up the inflammation—and pain—in the eye. Why Substance P Matters for Glaucoma and Ocular Discomfort Glaucoma itself is characterized by loss of retinal ganglion cells (RGCs) in the back of the eye (the retina). However, many people with glaucoma experience ocular surface symptoms unrelated to vision: dryness, burning, soreness, or red eyes. These often come from eye drop preservatives or inflammation from surgeries, and they can involve Substance P. For example, irritating drops or foreign substances on the eye surface make corneal nerves release more SP (), which then increases inflammation and pain. Studies show that when the ocular surface is inflamed, trigeminal nerves (the ones sensing the eye) begin to express much more Substance P () (). This creates a vicious cycleSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/glp-1-peptides-and-glaucoma-risk-what-we-know-and-what-to-watchTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Introduction GLP-1 receptor agonists (glucagon-like peptide-1 analogs) are a class of medicines originally developed to treat type 2 diabetes. By mimicking a natural gut hormone (GLP-1), drugs like semaglutide (Ozempic®, Wegovy®) and liraglutide (Victoza®, Saxenda®) help lower blood sugar and often cause weight loss 7{reference-type="ref"}. They are now used by millions of patients worldwide for diabetes and obesity. Interestingly, recent studies have observed that people taking these GLP-1 medicines seem to develop glaucoma – an eye disease that damages the optic nerve – less often than expected. In this article, we explain what GLP-1 agonists are, summarize the human evidence about glaucoma risk, describe how they might protect the eye, and discuss what kind of proof (randomized trials) is still needed. We also cover safety and regulatory issues. What Are GLP-1 Receptor Agonists? GLP-1 (glucagon-like peptide-1) is a natural hormone that helps the body release insulin and control appetite after eating. GLP-1 receptor agonists are medicines designed to act like GLP-1. Besides semaglutide and liraglutide, other examples include exenatide (Byetta®) and dulaglutide (Trulicity®). These drugs improve glycemic control (lower blood sugar) and often promote significant weight loss () (). Some newer GLP-1 agonists even come in pill form (e.g. oral semaglutide) (). Because they have “pleiotropic” effects, they also protect blood vessels and reduce inflammation in various parts of the body (). For instance, research in animals and humans has found that GLP-1 agonists improve heart and kidney health in diabetes (). GLP-1 RAs and the Eye GLP-1 receptors are present in many eye tissues, including nerve cells and blood vessel cells in the retina (). Laboratory studies show that activating these receptors can have powerful effects in the eye. GLP-1 drugs have anti-inflammatory, antioxidant, and neuroprotective actions in the retina (). For example, one experimental GLP-1 agonist (called NLY01) reduced damaging inflammation and prevented retinal ganglion cell death in a mouse model of glaucoma (). Another line of research found that GLP-1 analogs stabilize small blood vessels and the blood–retina barrier (the tight layer that protects the eye) (). In short, GLP-1 RAs have been shown to block multiple harmful processes in the eye – inflammation, oxidative stress, and nerve-cell damage – that are linked to glaucoma and other eye diseases () (). These findings have raised the idea that GLP-1 drugs might protect vision independently of their blood-sugar effects. Observational Evidence: Lower Glaucoma Rates Among GLP-1 Users? Several recent observational studies (looking at real-world patient data) have noted that people taking GLP-1 RAs develop glaucoma less often than similar patients who do not take them. For example, a U.S. insurance claims study compared about 1,961 new users of GLP-1 RAs to over 4,300 matched diabetic patients on other medications. After balancing the groups for age, gender, and diabetes control, the GLP-1 group had only 10 new cases of glaucoma (0.51%) versus 58 cases (1.33%) in controls. Statistically, this corresponded to a 44% lower hazard of glaucoma in the GLP-1 users (adjusted hazard ratio 0.56, 9Support the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/nerve-growth-factor-based-peptides-and-optic-nerve-protectionTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Introduction Glaucoma is a common cause of vision loss that happens when the retinal ganglion cells (RGCs) – the nerve cells connecting the eye to the brain – gradually die. As one review notes, glaucoma is “characterized by RGC degeneration and loss of visual field” (pmc.ncbi.nlm.nih.gov). In other words, patients slowly lose side vision and eventually central vision. Current glaucoma medicines all lower eye pressure, but doctors are actively looking for ways to protect the optic nerve cells directly. One idea is to use nerve growth factor (NGF), a natural protein that helps nerves survive and grow. NGF is like a fertilizer for certain nerve cells (pmc.ncbi.nlm.nih.gov). In healthy eyes it supports RGC survival – in glaucoma, NGF levels may drop, so adding extra NGF might slow RGC loss.NGF and Neuroprotection NGF is a small protein (a neurotrophin) that binds to receptors on neurons and tells them “grow and live.” Animal and lab studies show NGF “plays a crucial role in neuronal survival, differentiation, and growth” (pmc.ncbi.nlm.nih.gov). In the eye, retinal ganglion cells have NGF receptors, meaning they can respond when NGF is present. The idea is that supplying more NGF could neuroprotect these cells. In other words, NGF might block the cell-death signals in glaucoma and keep RGCs alive longer.... Continue reading at https://visualfieldtest.com/en/nerve-growth-factor-based-peptides-and-optic-nerve-protectionSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/heat-shock-protein-derived-peptides-and-autoimmunity-in-glaucomaTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Heat Shock Proteins and Immune Responses in Glaucoma Glaucoma is a leading cause of irreversible vision loss, affecting tens of millions of people worldwide (). Normally, glaucoma is linked to high eye pressure, but many patients – especially those with normal-tension glaucoma – have nerve damage despite normal pressure. This has led researchers to look beyond pressure and investigate the immune system’s role. In particular, eye experts have focused on heat shock proteins (HSPs), which are stress-related proteins that help keep nerve cells alive. Under some conditions these HSPs themselves may become targets of the immune system, contributing to nerve damage (). Evidence suggests that T cells (a type of white blood cell) reacting against HSPs can harm the optic nerve. For example, patient studies have found abnormally high levels of antibodies (proteins made by immune B cells) against HSPs in many glaucoma patients. In fact, multiple studies report that glaucoma patients often have elevated serum autoantibodies to HSP27 and HSP60, two common HSPs () (). In the lab, adding these patient antibodies to retinal cells can trigger cell death (), suggesting they are not just markers but may be damaging. In eye fluid (aqueous humor), glaucoma patients also show unique autoantibody “fingerprints,” including unusually high anti–HSP27 levels compared to healthy controls (). Taken together, these human findings point to an autoimmune tendency against HSPs in glaucoma. Evidence from Animal Models Studies in animals strongly support the idea that HSP-specific immune reactions can cause glaucoma-like damage. In classic experiments, scientists immunized healthy rats with HSP-derived peptides (for example, pieces of HSP27 or HSP60). Remarkably, these rats later developed nerve damage very similar to glaucoma () (). For instance, Wax and colleagues (2008) found that rats given HSP27 or HSP60 peptides lost large numbers of retinal ganglion cells (RGCs) – the neurons that form the optic nerve – and their axons in a pattern that closely mimics human glaucoma (). This damage occurred even though eye pressure stayed normal. Another group confirmed that immunizing rats with an optic-nerve extract (which contains many antigens, including HSPs) similarly caused RGC death and optic nerve thinning (). Importantly, these models also showed earlier immune changes: T cells infiltrated the retina days after immunization, and support cells (microglia) became activated, long before the neurons started dying () (). These animal experiments provide direct proof that an HSP-driven immune response can cause glaucoma-like neurodegeneration. Autoantibody Profiles in Patients Studies of glaucoma patients have found immune “signatures” consistent with HSP involvement. Many patients (especially with normal-tension glaucoma) carry autoantibodies against retina and optic nerve proteins, including HSPs () (). For example, researchers have detected antibodies to HSP27 and HSP60 in the blood of these patients (). In postmortem analyses, donor retinas from glaucoma patients showed antibody binding to HSP27 and HSP60 (). Laboratory tests imply these antibodies could be harmful: when anti-HSP27 antibodies from patients are applied to living retinal cells,Support the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/endothelin-pathway-peptides-and-optic-nerve-head-ischemia-in-glaucomaTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Endothelin-1 and Glaucoma: Blood Flow, Astrocytes, and Therapy Endothelin-1 (ET-1) is a very strong vasoconstrictor (makes blood vessels tighten) found naturally in the body. In the eye, ET-1 levels and signaling have been linked to damage in glaucoma, a disease of the optic nerve. Glaucoma often involves high intraocular pressure (IOP), but other factors – especially reduced blood flow and oxygen (ischemia) at the optic nerve head – can contribute. ET-1 can narrow small blood vessels around the optic nerve and in the retina, leading to poor oxygen supply. It also affects astrocytes, the support cells of the optic nerve, which can become overactive when stressed. In this article, we explain how ET-1 and its receptors (called ETA and ETB) are involved in glaucoma, how ET-1 interacts with nitric oxide (a blood‐vessel relaxer), evidence that ET-1 levels are higher in glaucoma patients, and finally how blocking ET-1 receptors might help protect the eye (along with the challenges of such treatments). How ET-1 Affects Eye Blood Flow ET-1 is produced by many eye tissues (retina, ciliary body, trabecular meshwork, etc.). It normally helps regulate blood flow and aqueous humor outflow. However, high ET-1 causes excessive vasoconstriction. For example, human lab studies found that injecting ET-1 into the eye rapidly decreases blood flow in the retina and optic nerve head (). Blood vessel narrowing leads to local ischemia (low oxygen), which can injure retinal ganglion cell (RGC) axons. ET-1 even has a direct toxic effect: it can trigger RGCs to undergo apoptosis (cell death) () (). Astrocytes – star-shaped glial cells in the optic nerve – also respond to ET-1. When ET-1 is high, astrocytes can multiply and change shape (a process called astrogliosis). This reactive gliosis can further harm the optic nerve environment. In lab cultures, ET-1 causes optic nerve astrocytes to proliferate, and this effect is blocked by either ETA or ETB receptor inhibitors (). In glaucomatous optic nerves (from humans and animals), researchers have observed more astrocyte proliferation and GFAP (a stress protein) when ET-1 is elevated (). Nitric Oxide and ET-1: Balancing Vessel Tone In healthy eyes, nitric oxide (NO) and ET-1 balance each other. NO is a vasodilator (it widens vessels), whereas ET-1 constricts them. Endothelial cells lining blood vessels release NO under normal conditions, relaxing the vessel walls (). Any disturbance in this balance – for example, too much ET-1 or too little NO – can impair blood flow. In the human ophthalmic (eye) artery, experiments showed that blocking NO causes vessels to constrict and that adding ET-1 causes strong constriction (). Thus, ET-1’s vasoconstriction can overcome NO’s dilating effect. Indeed, in glaucoma, impaired NO production (often due to endothelial dysfunction) is thought to worsen ET-1–induced ischemia. In some studies, giving ET-1 to people or animals reduced NO-mediated blood flow significantly, and an ETA-blocker (like BQ-123) could prevent that reduction (). This cross-talk means that high ET-1 disrupts the normal NO-driven relaxation, promoting a harmful cycle of poor blood supply. ET-1 Receptors: ETA and ETB Signaling ET-1 works by binding two main receptors on cells, Support the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/mots-c-and-glaucoma-a-mitochondrial-signal-with-bigger-implications-than-eye-pressureTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:MOTS-c and Glaucoma: A Mitochondrial Signal With Bigger Implications Than Eye Pressure? Glaucoma is an optic nerve disease often linked to high eye pressure, but it involves many cellular stress pathways. MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c) is a tiny peptide made by mitochondria that helps cells cope with stress. Could it influence glaucoma progression or vulnerability beyond just controlling pressure? This article examines the mechanistic links between MOTS-c and glaucoma. We separate established facts from indirect clues and educated speculation. Every big claim is cited to the literature. What MOTS-c Is In 2015, researchers discovered MOTS-c – a 16-amino-acid peptide encoded in mitochondrial DNA (mtDNA) (). It is produced from a short open reading frame in the mitochondrial 12S rRNA gene (). MOTS-c levels rise in response to stress or exercise and decline with age (). Under stress, MOTS-c moves from the mitochondria to the cell nucleus, where it helps activate antioxidant and stress-defense genes (). MOTS-c acts mainly through cellular energy sensors. It boosts the AMP-activated protein kinase (AMPK) pathway by diverting substrates toward AICAR production, mimicking a fasting/exercise signal () (). AMPK is a key regulator of energy balance in cells. When AMPK is activated, it in turn can increase PGC-1α, a master regulator of mitochondrial function (). Thus, MOTS-c indirectly drives cells to make more energy and repair mitochondria. MOTS-c also influences inflammation and oxidative stress. In cell studies, treating stressed cells with MOTS-c increased AMPK and PGC-1α levels and lowered reactive oxygen species (ROS) and inflammatory signals (). Specifically, MOTS-c reduced activation of NF-κB (a protein that drives inflammation) and cut levels of pro-inflammatory cytokines (like TNF-α, IL-1β, IL-6) while boosting anti-inflammatory IL-10 (). It can also activate NRF2 pathways, which turn on antioxidant defenses () (). In simpler terms, MOTS-c is a stress-adaptive hormone made by mitochondria. It helps cells cope with metabolic and oxidative challenges by fueling energy production and calming inflammation () (). It is being studied for benefits in diabetes, neurodegeneration, and aging-related conditions () (). However, its role in eye diseases (especially glaucoma) is not established. Why Glaucoma Might Intersect with MOTS-c Glaucoma damages the optic nerve and kills retinal ganglion cells (RGCs). Classic glaucoma causes are high intraocular pressure (IOP) and aging, but pressure-independent factors also play a major role. Key features of glaucoma biology may interact with what MOTS-c does: Retinal Ganglion Cell Energy Needs: RGCs have high metabolic demand. Their unmyelinated axons use many ATP-driven ion pumps and are packed with mitochondria (). These cells depend heavily on oxidative phosphorylation (OXPHOS) for energy (). If mitochondria falter, RGCs quickly suffer. In principle, MOTS-c’s ability to boost mitochondrial energy production could protect such high-demand neurons. (This is speculative: RGC-specific data on MOTS-c are lacking.) Mitochondrial Dysfunction in Glaucoma: A growing body of evidence implicates mitochondrial failure iSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/senolytics-and-the-glaucoma-niche-clearing-old-cells-for-longer-life-signalsTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Introduction Glaucoma is an age-related eye disease in which high pressure in the eye (intraocular pressure, or IOP) damages retinal nerve cells and leads to vision loss. Aging is the single biggest risk factor for glaucoma, and new research suggests this may be because aging eyes accumulate senescent cells – cells that have permanently stopped dividing and secrete inflammatory signals. Cellular senescence is a normal response to damage or stress, but when these old cells build up they release a mix of molecules called the senescence-associated secretory phenotype (SASP). SASP factors include inflammatory cytokines (like interleukin-6), growth factors (like TGF-β) and enzymes that remodel tissue. In eye tissues such as the trabecular meshwork (TM) (the drainage canal that controls IOP) and the optic nerve head (ONH) (where retinal ganglion cell axons exit the eye), senescent cells and their SASP appear to drive chronic inflammation and scarring. For example, one recent review noted that both TM cells and retinal ganglion cells in aging eyes show markers of senescence, and clearing those old cells improved retinal ganglion cell survival in animal models () (). This article reviews the evidence that senescence contributes to glaucoma and explores how senolytic therapies – drugs that specifically kill senescent cells – might help protect the eye. Senescence in the Glaucoma Niche Trabecular Meshwork Senescence The trabecular meshwork (TM) is a sponge-like tissue that drains fluid from the eye. With normal aging, TM cell numbers gradually decline and the meshwork develops thick, stiff extracellular material. Histological studies show that older eyes have far fewer TM cells than young eyes, and this loss is much greater in glaucoma patients (). When TM cells die or senesce and are replaced by scar-like matrix, the drainage channel narrows and IOP rises (). In fact, Zhang et al. describe how an “absence of TM cells, followed by their replacement with extracellular matrix, leads to increased resistance to fluid outflow” (). This fits with clinical observations that the aging outflow pathway becomes fibrotic (for example, accumulation of type VI collagen is seen in glaucomatous TM) and raises IOP (). Laboratory studies of TM cells have identified classic features of senescence in aging or stressed cells: enlarged shape, cell-cycle arrest, and expression of markers like p16^INK4a. Importantly, senescent TM cells unleash pro-inflammatory SASP factors. For example, senescent TM cells have been shown to overproduce interleukin-6 (IL-6), IL-8 and chemokines (CCL2, CXCL3) (). These cytokines can recruit immune cells and drive fibrotic signaling (notably TGF-β is also part of the ocular SASP). Such chronic inflammation likely stiffens the TM. In short, aged and diseased TM tissue accumulates senescent cells that secrete fibrosis-inducing signals, contributing to outflow obstruction and elevated IOP () (). Optic Nerve Head and Retina Senescence Glaucoma also damages the optic nerve head (ONH) and retinal ganglion cells (RGCs) that send signals from the eye to the brain. Aging affects these tissues too. RGCs in older eyes show more oxidative damage and are less able to survive stress (). Senescent cells Support the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/ketogenic-signals-and-beta-hydroxybutyrate-iop-neuroprotection-and-longevity-intersectionsTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Ketogenic Diet and Retina: Protecting Eye Nerves through Metabolism Glaucoma is an eye disease where pressure or other factors cause progressive damage to the retinal nerve cells (retinal ganglion cells, RGCs) and their fibers, leading to vision loss. Traditionally, treatment focuses on lowering eye pressure (intraocular pressure, IOP). Recently, researchers have explored whether changing body metabolism – for example with a ketogenic diet or ketone supplements – could help protect RGCs. A ketogenic diet is very low in carbohydrates and high in fats. In response, the body burns fat and produces ketone bodies (like beta-hydroxybutyrate or BHB) as a fuel. Ketones can serve as an alternative energy source for the brain and eyes. Emerging evidence suggests these metabolic changes can boost cell energy use, quiet harmful overactivity (excitotoxicity), and even alter gene activity, in ways that may shield RGCs from damage () (). In animal studies, ketone treatments have improved RGC survival and function. In other model systems, BHB shows broad anti-inflammatory and “longevity” effects. In this article we explain these findings in plain terms, and discuss what they mean for glaucoma patients – especially those who are older or have other health issues. Fueling Mitochondria: Energy Efficiency and Retinal Health The retina, especially RGCs, is a highly active tissue that needs a lot of energy to work. This energy comes from tiny structures in cells called mitochondria. If mitochondria work better, nerve cells are healthier. Ketones are a special fuel for mitochondria. They can be turned into energy efficiently, sometimes even more cleanly than sugar. A number of studies have shown that ketogenic metabolism boosts mitochondrial function. For example, one study in mice used a glaucoma model and found that a ketogenic diet promoted both mitochondrial biogenesis (making new mitochondria) and mitophagy (recycling damaged mitochondria) in RGCs (). In that glaucoma model, mice eating a high-fat, low-carb diet kept more RGCs alive than control mice. The investigators noted increased mitochondrial markers and better energy balance in those cells () (). In simpler terms, the ketogenic diet gave the eye nerves a metabolic “upgrade” – more and healthier mitochondria that could meet energy needs under stress. Animal research also links ketosis to better antioxidant defenses (fighting cell damage). For example, a scientific review points out that ketogenic metabolism can lower production of harmful reactive oxygen species, and boost cell-protective pathways () (). In experimental glaucoma (an inherited model in DBA/2J mice), mice on a ketogenic diet showed healthier mitochondria and more antioxidant response compared to controls (). These changes were accompanied by better RGC survival. This suggests that providing ketones – either through diet or supplements – may make retinal neurons more energy-efficient and resistant to stress () (). Calming Excitotoxicity: Dampening Overactive Nerve Signals Another stress factor for neurons is excitotoxicity. This happens when too much glutamate (a common nerve messenger) overexcites cells and leads to injury. In glaucoma and other neurodSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/the-glaucoma-energy-crisis-how-pyruvate-rescues-failing-eyes-and-why-your-fitness-level-mattersTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Demand-Driven Metabolism: Why 3g of Pyruvate Won’t “Rev Up” a Couch Potato Your cells are like a precisely-tuned factory, only cranking out ATP (the cellular “energy currency”) when there’s work to do. If you’re sedentary and not using extra energy, simply swallowing a few grams of pyruvate won’t flood cells with power. In fact, cells regulate their energy supply very tightly. High levels of ATP actually shut down key energy pathways: for example, abundant ATP inhibits the enzyme pyruvate dehydrogenase (PDH) and instead activates pyruvate carboxylase (). In plain terms, if the “battery” (ATP) is already full, the cell stops using fuel. Extra pyruvate then gets shunted into storage or recycled rather than magically generating a feeling of buzz. In short, cellular energy production is strictly demand-driven. Even if you load up on pyruvate, an inactive body won’t convert it to extra ATP unless it’s needed. Instead, the surplus pyruvate enters normal metabolic “overflow” routes, including: Gluconeogenesis (Glucose Synthesis): In the liver, pyruvate (often via lactate) can be converted back into glucose to maintain blood sugar levels. This involves carboxylating pyruvate to oxaloacetate and eventually making glucose (). It’s an energy-intensive process – the body won’t do it without reason. Lactate Cycle: Excess pyruvate in muscles can be turned to lactate, which is shuttled to the liver and made into glucose, recycling energy. This prevents a build-up of metabolic waste and helps maintain blood glucose in rest. Fat Synthesis (Minor Route): Only in situations of chronic, massive over-supply does pyruvate contribute to fat. Experimentally, adipose tissue barely converts pyruvate into fatty acids unless its concentration is extremely high (tens of mM) (). In practical terms, a 3 g supplement won’t flood your blood with enough pyruvate to trigger significant fat storage. Gastrointestinal Effects: Strong organic acids can upset the stomach if overdone. High supplemental doses (dozens of grams) are known to cause gas, bloating or diarrhea (). In most studies, moderate doses (a few grams) are well-tolerated, but any abrupt high-dose intake could irritate the gut. The bottom line: If your cells don’t need more ATP, extra pyruvate is either turned back into sugar (used later) or simply stored without giving you a noticeable energy boost. The body won’t just burn it for no reason, and at high doses one might just feel tummy trouble (). The Glaucoma Energy Crisis: A Localized Shortage in the Retina In glaucoma, the optic nerve – built from retinal ganglion cells (RGCs) – faces a unique energy bottleneck. RGCs are extreme energy hogs: they fire constantly, maintain big voltage differences, and transmit visual signals non-stop. In fact, the retina is physiologically the most energy-hungry tissue in the body () (). One review notes that “the retina is the highest oxygen-consuming organ in the human body” and inner retinal neurons (like RGCs) have “the highest metabolic rate of all central nervous tissue” (). Simply put, RGCs are like high-powered computers that never sleep. They need large ATP supplies just to keep their ion pumps running and signals flowing (). With age and gSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/photobiomodulation-670-nm-for-aging-retina-lifespan-signals-from-flies-to-mammalsTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Introduction As we age, eye cells gradually lose energy and function, partly because their mitochondria (the cell’s “batteries”) become weaker (). This is true in the retina – the light-sensitive tissue at the back of the eye – where dying mitochondria contribute to poorer vision and diseases like age-related macular degeneration (AMD). Photobiomodulation (PBM) is a gentle therapy that uses low-intensity red or near-infrared light (usually around 670 nm wavelength) to stimulate cells. Laboratory studies suggest that shining 670 nm light into the eye can recharge mitochondrial function, boosting energy (ATP) production and easing inflammation () (). In practical terms, this therapy is often done with LED lamps or lasers positioned near the eye for a few minutes each day. Early experiments – from simple flies to mice and small human trials – hint that PBM might improve retinal health and even aspects of whole-body aging. This article reviews how 670 nm light benefits photoreceptors and retinal ganglion cells, summarizes results in experimental models (including lifespan effects in insects), and discusses dosing, safety, and possible home use. Finally, we suggest future studies that combine vision tests with markers of mitochondrial health to see if this light can boost not just eyesight, but overall cellular “youth.” How near-infrared light boosts retinal cells Photobiomodulation at 670 nm targets mitochondria, the tiny structures inside cells that make most of our energy (ATP). In mitochondria, a key enzyme called cytochrome c oxidase absorbs red/near-infrared light, which helps it run more efficiently () (). In effect, 670 nm light raises the electrical membrane potential of mitochondria and lets them crank out more ATP () (). Studies show this extra energy relieves age-related decline: for example, one report found that a month of daily 670 nm light in old mice roughly corrected their low mitochondrial membrane potential and ATP levels (). In addition, energized mitochondria produce fewer harmful free radicals, so treated cells show less oxidative stress and inflammation () (). Photoreceptors (the retina’s light-sensing rods and cones) and retinal ganglion cells (RGCs, the nerves that carry visual signals to the brain) are high-energy cells packed with mitochondria. By boosting mitochondrial activity, 670 nm light helps these cells work more efficiently. Lab studies find that photobiomodulation can directly improve photoreceptor metabolism and survival. For instance, in a mouse model of light-induced retinal damage, 670 nm treatment greatly improved photoreceptor health: treated cells had stronger mitochondrial respiration and less stress-induced damage (). Likewise, in an optic-nerve injury model, 670 nm light preserved RGCs: treated rats showed a 3.4-fold increase in visual signal strength and 1.6 times more surviving RGCs, along with higher retinal ATP levels and antioxidant markers (). In summary, by dialing up mitochondrial efficiency in these retina cells, photobiomodulation can make aged or stressed eye cells behave more like young, healthy ones. Results from animal studies Researchers have tested 670 nm PBM in various aging and disease models with encouraging results. In aged micSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/what-s-new-in-glaucoma-research-in-april-2026-what-patients-should-knowTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:What’s New in Glaucoma Research in April 2026? What Patients Should Know Glaucoma is a group of eye diseases that slowly damage the optic nerve, often due to high pressure inside the eye. It’s sometimes called the “silent thief of sight,” because vision can go gradually without you noticing (). Worldwide, glaucoma is a leading cause of irreversible blindness – in fact it’s the second-most common cause of blindness globally (after cataracts) (). Researchers are always looking for new clues about how it works and how to catch or treat it earlier. In April 2026, several new studies made headlines. We explain them in plain language below. (For context, note that a January 2026 study found the enzyme GPX4 – glutathione peroxidase 4 – helps protect eye nerve cells from damage (). But that study is from January, not the April updates.) Tiny Blood Vessel Leaks and Glaucoma Damage What the study found: A new research report suggests that tiny leaks in tiny blood vessels in the eye may contribute to glaucoma damage. In simple terms, researchers observed that microscopic blood vessels in the retina (the back of the eye) can become slightly leaky. This leak could let fluid or blood components escape into parts of the eye where they shouldn’t be. Over time, such leaks might stress or damage the optic nerve fibers. (Think of it like very small blood vessel “drips” that harm delicate tissue nearby.) Why it matters: We usually think of glaucoma damage as due to pressure; this study hints that blood vessel health is also important. If true, it could open new treatment ideas (for example, medicines to strengthen those vessels or reduce leakage). It’s an unusual idea in glaucoma research, so it’s still early-stage. It reminds us that glaucoma might involve more than just simple pressure – the circulation in the eye may play a role. How it was studied: This kind of research is usually done in laboratory models (animals or cell/tissue tests), not yet in people. The study did tests on eye tissue (or possibly in animals) to look for leaks under a microscope. (Because it’s new and detailed work, it’s not a large human trial.) Patient impact now: Right now, this finding does not change how we treat glaucoma. It’s a clue in the lab. Patients should continue their usual pressure-lowering treatments. In the future, if this line of research pans out, doctors might test additives that protect those tiny vessels. Big-picture importance: On a scale of 1–10 (10 = game-changing, 1 = interesting but small), this gets about a 5/10. It’s intriguing because it suggests a new mechanism, but it’s still early. More research will be needed to know if vessel leaks are a major factor in most glaucoma cases or only a minor one. A Possible Nerve-Protecting Drug (WAY-100635) What the study found: Another April 2026 study looked at a drug called WAY-100635 (pronounced “way-ten-thousand-six-hundred-thirty-five”). This compound affects serotonin receptors in the brain, but researchers tested it to see if it could protect eye nerve cells. In lab tests, giving WAY-100635 seemed to shield retinal ganglion cells (the neurons that form the optic nerve) from damage caused by glaucoma-like stress. In other words, in their experiments, eyes Support the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/a-new-clue-in-glaucoma-leaky-blood-vessels-may-damage-visionTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:A New Clue in Glaucoma: Leaky Blood Vessels May Damage Vision Glaucoma is known as the “silent thief of sight,” slowly damaging the eye’s nerve cells and causing vision loss. Today new research hints at surprising factors that could help protect vision or even restore it. In April 2026, scientists reported several findings that may affect how we understand and treat glaucoma. These include a study linking leaky tiny blood vessels to nerve damage, a tested drug (WAY-100635) that helps keep nerve cells alive, and an artificial intelligence (AI) tool to catch glaucoma earlier. We’ll explain each in plain language, note how close they are to helping patients, and give each finding an importance rating (1–10) for the big picture. We’ll also briefly mention a January 2026 study on a protective enzyme (GPX4) from past news. Leaky Retinal Blood Vessels and Glaucoma (Importance: 6/10) One new idea is that damage to small retinal blood vessels might contribute to glaucoma. Normally, the tiny blood vessels in the retina have tight barriers that keep fluid and cells from leaking into the delicate nerve layer. But if this “blood-retinal barrier” breaks down, harmful substances or immune cells could slip through and hurt the retinal ganglion cells (RGCs) – the nerve cells lost in glaucoma. A recent lab study found evidence for this effect. In experiments on mice, researchers showed that removing certain immune cells (microglia) caused retinal vessels to become leaky after injury (). This leakiness allowed inflammation in the retina and actually reduced the ability of nerve cells to regrow their connections. In other words, when the blood vessels leaked, nerve repair was worse. The study highlighted that keeping the vessels sealed is important for nerve protection. It’s important to note this was early lab work (in mice) looking at injury models, not human trials. Still, it suggests that future glaucoma treatments might also aim to strengthen vessel barriers or control inflammation. Despite being only in the lab so far, this finding is interesting because it adds a new clue to what makes glaucoma worse. (Rating: about 6/10 – it’s an early discovery that opens new research ideas, but far from direct patient treatments.) A healthy blood-retinal barrier has long been known as critical in diabetes and retinal diseases (), and now it’s being studied in glaucoma too. Drug WAY-100635 Protects Nerve Cells (Importance: 7/10) Another April 2026 result came from a drug screen on retinal nerve cells. Scientists tested a series of compounds on human-like retinal ganglion cells grown in the lab. They found that WAY-100635, a drug originally studied in the brain, helped these glaucoma-vulnerable nerve cells survive and function better. Specifically, the drug boosted the cells’ energy factories (mitochondria) and reduced their suicide signals. The study () (published 02 April 2026 in Communications Medicine) used both cell cultures and mouse models of optic nerve injury and glaucoma. When mice were given WAY-100635, their retinal ganglion cells were better protected after damage. Importantly, treated mice kept more of their vision: tests showed their eyes could still send signals to the brain with much less loss. In simple terms, WAY-100635 acted like a “neuroprotectoSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/april-2026-glaucoma-trial-launches-a-global-landscape-reviewTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:April 2026 Glaucoma Trial Launches: A Global Landscape Review Glaucoma is a leading cause of irreversible blindness worldwide. An estimated 76 million people had glaucoma in 2020, with that number projected to exceed 111 million by 2040 (). Most glaucoma treatments work by lowering intraocular pressure (IOP), the fluid pressure inside the eye, but new therapies aim to protect nerve cells and preserve vision. In April 2026 dozens of new glaucoma clinical trials officially began in registries around the world (ClinicalTrials.gov, EU CTR, ISRCTN, ANZCTR, CTRI, ChiCTR, WHO ICTRP). These trials span a range of intervention types – including new medications, implants and devices, surgical procedures, and digital health tools – and together paint a picture of current research priorities. New Trials by Modality The April 2026 trials can be grouped by their main intervention modality: Drug (Medication) Trials: The largest category remains medication studies. These include novel eye drops that lower IOP (for example new prostaglandin analogues or rho-kinase inhibitors) as well as systemic drugs being repurposed. Recent years have seen interest in metabolic and neuroprotective agents – for example, trials of oral diabetes drugs (GLP-1 agonists) or vitamins that may protect retinal nerve cells () (). Some trials involve sustained-release formulations (tiny implants that slowly release IOP-lowering drugs). For instance, one ongoing Phase II study is testing a tiny biodegradable implant (“TimoD”) that slowly releases the glaucoma drug timolol (). Overall, most new trials are early-stage (Phase I/II) safety and efficacy studies of such medications and delivery systems. Device Trials: A substantial portion of trials involve medical devices and implants. This includes micro-invasive glaucoma surgery (MIGS) devices, drainage stents and shunts, and laser or ultrasound systems to improve outflow. Examples might be trials of new canaloplasty implants or trabecular bypass stents, or innovative lasers (like excimer laser trabeculotomy) that create tiny drains in the trabecular meshwork. Many device trials test ways to restore the eye’s natural drainage (e.g. new iris-to-canal shunts) or to replace medications with implants. These often require surgical implantation but are generally less invasive than traditional trabeculectomy. Surgical and Procedural Trials: Some studies focus on surgical techniques rather than implants. These include comparisons of different glaucoma surgeries (for example combined cataract–glaucoma procedures versus standard surgery), or novel approaches like minimally penetrative trabeculotomies. A few are evaluating high-intensity focused ultrasound or other non-implant procedures to lower IOP. (In practice there is overlap with device trials, since many surgical trials involve an implanted device.) Digital and Diagnostic Trials: A growing niche is digital health. These trials evaluate tools like smartphone perimetry apps, home tonometry devices, AI algorithms for image screening, or telemedicine programs for remote care. For example, a recent trial is using an AI system to flag glaucoma from routine retinal photos in primary care clinics. A systematic review found 21 published studies of home-based glaucoma moniSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/april-2026-glaucoma-trial-launches-a-global-landscape-reviewTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:April 2026 Glaucoma Trial Launches: A Global Landscape Review Glaucoma is a leading cause of irreversible blindness worldwide. An estimated 76 million people had glaucoma in 2020, with that number projected to exceed 111 million by 2040 (). Most glaucoma treatments work by lowering intraocular pressure (IOP), the fluid pressure inside the eye, but new therapies aim to protect nerve cells and preserve vision. In April 2026 dozens of new glaucoma clinical trials officially began in registries around the world (ClinicalTrials.gov, EU CTR, ISRCTN, ANZCTR, CTRI, ChiCTR, WHO ICTRP). These trials span a range of intervention types – including new medications, implants and devices, surgical procedures, and digital health tools – and together paint a picture of current research priorities. New Trials by Modality The April 2026 trials can be grouped by their main intervention modality: Drug (Medication) Trials: The largest category remains medication studies. These include novel eye drops that lower IOP (for example new prostaglandin analogues or rho-kinase inhibitors) as well as systemic drugs being repurposed. Recent years have seen interest in metabolic and neuroprotective agents – for example, trials of oral diabetes drugs (GLP-1 agonists) or vitamins that may protect retinal nerve cells () (). Some trials involve sustained-release formulations (tiny implants that slowly release IOP-lowering drugs). For instance, one ongoing Phase II study is testing a tiny biodegradable implant (“TimoD”) that slowly releases the glaucoma drug timolol (). Overall, most new trials are early-stage (Phase I/II) safety and efficacy studies of such medications and delivery systems. Device Trials: A substantial portion of trials involve medical devices and implants. This includes micro-invasive glaucoma surgery (MIGS) devices, drainage stents and shunts, and laser or ultrasound systems to improve outflow. Examples might be trials of new canaloplasty implants or trabecular bypass stents, or innovative lasers (like excimer laser trabeculotomy) that create tiny drains in the trabecular meshwork. Many device trials test ways to restore the eye’s natural drainage (e.g. new iris-to-canal shunts) or to replace medications with implants. These often require surgical implantation but are generally less invasive than traditional trabeculectomy. Surgical and Procedural Trials: Some studies focus on surgical techniques rather than implants. These include comparisons of different glaucoma surgeries (for example combined cataract–glaucoma procedures versus standard surgery), or novel approaches like minimally penetrative trabeculotomies. A few are evaluating high-intensity focused ultrasound or other non-implant procedures to lower IOP. (In practice there is overlap with device trials, since many surgical trials involve an implanted device.) Digital and Diagnostic Trials: A growing niche is digital health. These trials evaluate tools like smartphone perimetry apps, home tonometry devices, AI algorithms for image screening, or telemedicine programs for remote care. For example, a recent trial is using an AI system to flag glaucoma from routine retinal photos in primary care clinics. A systematic review found 21 published studies of home-based glaucoma moniSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/therapeutic-mechanisms-debuting-in-april-2026-glaucoma-trialsTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Introduction Glaucoma is a chronic eye disease in which pressure buildup (intraocular pressure, or IOP) damages the optic nerve, leading to vision loss. Standard treatments focus on lowering IOP by helping fluid drain out of the eye or reducing fluid production. In 2026, several new clinical trials are testing novel approaches beyond the usual medications. These include drugs and devices that enhance outflow, suppress inflow, prevent scarring (anti-fibrotics), protect the optic nerve (neuroprotective), and improve blood flow to the nerve (vascular modulators). Each strategy has a clear laboratory rationale and often positive early human data. For example, nitric-oxide–donating prostaglandins (like NCX 470) and Rho-kinase (ROCK) inhibitors aim to widen the trabecular meshwork or veins to enhance drainage () (). Neuroprotective strategies (such as high-dose vitamin B3 or GLP-1 agonists) have shown in animal models that they can preserve retinal nerve cells even without pressure changes () (). Below we summarize each mechanism, its rationale, early evidence, and how trials measure success (e.g., IOP patterns, nerve imaging or visual fields), along with key safety issues. Outflow Enhancers What it is. These treatments aim to improve fluid drainage through the eye’s natural outflow channels (trabecular meshwork and Schlemm’s canal) or add new paths. Enhanced outflow lowers IOP without directly reducing fluid production. Examples include new eyedrop drugs and micro-invasive surgical devices. Rationale (preclinical and early data). Preclinical studies show that relaxing the trabecular meshwork or dilating outflow veins can dramatically increase fluid outflow. For instance, rock inhibitors like netarsudil relax cellular tension in the drainage tissue – in clinical trials they lowered IOP as well as timolol (a gold-standard medicine) (). Another example is QLS-111, an ATP-sensitive potassium-channel opener that dilates veins and may reduce the downstream pressure on Schlemm’s canal (). In Phase II human trials, QLS-111 added to latanoprost dropped IOP by several mmHg (). Device approaches (like suprachoroidal implants or laser trabeculoplasty) physically widen or reopen drainage channels, and early studies in animals and humans show pressure falls and improved outflow on imaging. ... Continue reading at https://visualfieldtest.com/en/therapeutic-mechanisms-debuting-in-april-2026-glaucoma-trialsSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/gene-and-cell-based-therapies-entering-glaucoma-trials-in-april-2026Test your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Gene- and Cell-Based Glaucoma Trials (April 2026) Emerging gene and cell therapies hold promise for glaucoma – a disease that slowly destroys the retinal ganglion cells (RGCs) (the nerve cells sending vision signals to the brain) and impedes the eye’s natural drainage of fluid (the aqueous outflow pathways). These next-generation treatments aim either to protect or regenerate RGCs (neuroprotection) or to improve outflow tissue function and lower intraocular pressure. In April 2026 several first-in-human trials will begin for such approaches. Below we summarize their main features – vectors, molecular targets, dosing plans and immune safety measures – as well as how they are delivered and controlled. We also note the ethical issues of sham controls and the required long-term safety monitoring. Gene Therapy for RGC Neuroprotection Some trials deliver genes encoding neuroprotective factors into the eye to help RGCs survive. For example, one approach uses a harmless viral vector (often an adeno-associated virus, AAV) to carry the gene for ciliary neurotrophic factor (CNTF) or brain-derived neurotrophic factor (BDNF) into retinal cells. These proteins act like growth factors to keep RGCs healthy. (Indeed, laboratory studies report that factors such as BDNF and glial cell–derived neurotrophic factor (GDNF) can greatly improve RGC survival ().) In an upcoming Phase 1 trial, for instance, patients will receive an intravitreal (into the gel of the eye) injection of an AAV vector carrying the human CNTF gene. The trial is dose-escalating: each group of patients will get a higher viral dose to find the safe and active range (typical Phase 1 design). Blood and eye exams will regularly check for immune reactions – for example, measuring if the body makes antibodies (binding or neutralizing) against the viral capsid or the new gene product (). Many ocular gene trials also use short courses of corticosteroid eye drops around the time of injection to blunt inflammation () (). Another putative gene therapy targets the neuronal degeneration process itself. For instance, trials may deliver genetic “braking” tools (like short hairpin RNA or CRISPR nucleases) to suppress harmful signals in RGCs. One example in animal studies used an AAV-delivered Cas9 gene-editing system to knock out the Wallerian degeneration pathway (which causes axons to die after injury). In mice, such treatments kept RGC axons more intact. Key points: gene therapies for RGCs typically use intravitreal or subretinal injections (small-eye surgery akin to injections for macular degeneration ()) and monitor vision function by elective tests (imaging, visual field, etc.) over time. Because gene expression is long-lasting, trials plan extended follow-up. FDA guidance, for example, calls for up to 15 years of post-treatment monitoring in gene therapy trials, focusing on late adverse events like tumor development (). A registry of treated patients may also be kept to flag any rare issues. Gene Therapy for Aqueous Outflow / IOP Lowering Other April 2026 trials aim at lowering eye pressure by improving the drainage of fluid. These target the trabecular meshwork and Schlemm’s canal (the tissues in the iridocorneal angle that normally let aqueous fluid exit the eye)Support the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/home-tonometers-and-contact-lens-sensors-in-april-2026-protocolsTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Introduction Glaucoma management is evolving with home-based intraocular pressure (IOP) monitoring. Traditionally, eye pressure is checked only during office visits, but new devices let patients measure IOP at home or wear sensors in their eyes. In fact, by 2026 several clinical trials began incorporating these technologies. Home tonometers (like the FDA-approved iCare HOME rebound tonometer ()) allow patients to check their own IOP without anesthesia. Smart contact lenses equipped with sensors (e.g. the Sensimed Triggerfish® CLS) can continuously record 24-hour pressure patterns (). These trials explore how such data can improve efficacy outcomes and trigger safety interventions, while ensuring data quality and patient comfort. Trials with Home IOP Monitoring Several recent and upcoming trials (starting around April 2026) include home tonometry in their protocols. For example, an academic study at Wills Eye Hospital is testing home monitoring for mild‐to‐moderate glaucoma patients. Participants use the iCare HOME tonometer at home, measuring IOP multiple times and uploading data, alongside a portable perimeter for visual field testing (). Similarly, a large Guangdong/Hong Kong trial randomizes newly diagnosed glaucoma patients to (1) home telemonitoring with iCare HOME plus a smartphone coaching program, or (2) standard care with smartphone support (). In that trial, patients in the home-monitoring arm upload six IOP readings weekly (two days per week, thrice daily) to a secure cloud platform (iCare CLINIC) (). Another “diurnal monitoring” trial in Switzerland (NCT04485897) compares 24-hour hospital-based IOP monitoring to patient self-tonometry at home. In that study, patients use the iCare device on themselves and investigators analyze how well the home pressure curve matches the clinic curve (). These and other trials explicitly incorporate home IOP data into their endpoints and decision rules. Trials with Continuous Contact-Lens Sensing A parallel line of research uses smart contact lenses to measure IOP continuously. For example, the Mon-BH/Barcelona ISRCTN65401232 trial is studying glaucoma patients who undergo minimally invasive iStent surgery. Both the surgery group and a control group get 24-hour monitoring with the Sensimed Triggerfish® contact lens sensor at baseline and follow-up (e.g. 1 or 3 months later) (). The Triggerfish is a soft silicone lens (~14.1 mm diameter, 585 μm thick) embedded with micro-strain gauges, a chip, and an antenna (). It transmits pressure-related data to an adhesive orbital antenna and portable recorder worn by the patient (). Such trials use the sensor output to quantify circadian IOP patterns. For instance, the Spanish iStent trial defines the primary outcome as the amplitude of a fitted 24-hour IOP curve derived from the lens data (). In short, modern protocols combine traditional endpoints (like average IOP or nerve fiber thinning) with novel continuous IOP measurements from these contact lenses. Device Specifications and Calibration Home tonometers such as the iCare HOME are rebound tonometers: a lightweight handheld probe gently bounces a small disposable tip off the cornea to compute pressure (). The iCare HOME (model TA022) was FDA-cleared in 2017 () and comes with disposaSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/washout-and-rescue-protocols-in-april-2026-iop-lowering-studiesTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Introduction Clinical trials of new glaucoma (intraocular-pressure–lowering) medications often pause patients’ existing eye drops to establish a clear “untreated” baseline pressure. This is known as a washout period (). By measuring eye pressure after stopping prior treatment, researchers can accurately judge how much the new drug lowers pressure. However, taking patients off therapy raises safety concerns (pressure can rebound) and can cause some people to fail screening. Trials therefore include strict rescue rules (to restart treatment if pressure gets too high) and careful monitoring. Understanding these washout and rescue protocols helps explain why trial results may differ from everyday practice. Washout Durations and Sequences by Medication Class Trials use different washout lengths for different drug classes, based on how long medications linger in the eye. In general: Prostaglandin analogs (PGAs) (e.g. latanoprost, travoprost, bimatoprost): Washout periods are often around 4 to 8 weeks. A systematic review found that patients typically returned to baseline pressure about 4–5 weeks after stopping latanoprost (). However, PGA effects can variably persist — one study found some patients still had slightly lowered pressure 8 weeks after stopping latanoprost (). Travoprost and bimatoprost also generally need several weeks; most studies use ~4 weeks, although evidence is limited (). Patients on PGAs may undergo multiple checks up to 6–8 weeks after stopping. Beta-blockers (e.g. timolol): These are typically washed out by stopping the drop for 4 weeks. Research showed that a 2-week break is usually too short (). After stopping timolol, pressure often edges back toward a higher baseline by 3–4 weeks. Alpha-2 agonists (brimonidine): These often require about 4–5 weeks off. In one trial, 15 patients washed out brimonidine over 5 weeks to reach baseline (). Carbonic anhydrase inhibitors (CAIs) (dorzolamide, brinzolamide): Although less well studied, trials commonly use around 2–4 weeks off, as their effects diminish more quickly than PGAs. Miotics (e.g. pilocarpine): These have a very short duration of effect. Usually a break of 1–2 weeks suffices. (Miotics are rarely used long-term today.) In trials where patients are on more than one medication, the protocols may pause all drops at once or sometimes stagger them. Typically all prior medications are stopped together and sufficient time is allowed for the slowest drug to clear. The washout lengths above are chosen so that most patients return to their true “untreated” IOP. As noted by Stewart et al., too short a washout might make a new drug look less effective, while an unnecessarily long washout only prolongs high risk pressure (). Stewart and colleagues found, for example, that stopping brimonidine needed about 5 weeks to return to baseline, whereas stopping latanoprost sometimes took up to 8 weeks (). (They also showed that travoprost effects were not fully gone after 2 weeks ().) Because evidence is limited, many trials simply follow “industry standards” (often 4–6 week washouts for PGAs and 4 weeks for older drugs) based on these and other data. Rescue Criteria and Safety Monitoring During washout, patient safety is paramount. Trials define rescue criteria Support the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/hyperbaric-oxygen-therapy-and-glaucoma-mechanistic-rationale-and-biological-plausibilityTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Introduction Hyperbaric oxygen therapy (HBOT) is a medical treatment in which a person breathes nearly 100% oxygen inside a pressurized chamber (usually 1.5–3 times normal atmospheric pressure). This increases the amount of dissolved oxygen in the blood and tissues () (). HBOT has approved uses (like treating carbon monoxide poisoning or wound healing) and experimental uses in eye diseases, but its effects on glaucoma (a disease of the optic nerve) are not well established. Glaucoma involves progressive loss of retinal ganglion cells (the nerve cells in the back of the eye) and their axons, often associated with high eye pressure or poor blood flow (). In theory, raising oxygen levels in the retina and optic nerve head could help cells survive stress, but excess oxygen can also cause harm. This article explores how HBOT changes eye oxygen levels, blood flow, and cellular metabolism, and what that might mean for glaucoma – weighing the potential benefits and risks. HBOT and Oxygen in the Eye The retina (nerve layer lining the back of the eye) is extremely active metabolically and needs a lot of oxygen () (). Under normal conditions, the inner retina (including ganglion cells) gets oxygen from the small retinal arteries, while the outer retina (photoreceptors) gets it from the choroid (a dense layer of blood vessels beneath the retina). When someone undergoes HBOT, the air they breathe has very high oxygen partial pressure. This dramatically increases the oxygen carried by the blood and dissolved in the eye’s fluids (). For example, HBOT can saturate the vitreous gel (inside the eye) and even replace nitrogen with oxygen, so that oxygen levels in the eye remain elevated for hours (). One review notes that “tissue oxygen level has been observed to remain high for up to 4 hours after therapy” (). In effect, the eye has an unusually large oxygen reserve. For glaucoma, higher oxygen in the optic nerve head and retina might influence cell survival. In an oxygen-rich environment, cells may make more energy (ATP) via their mitochondria and resist low-oxygen damage. In animal models, HBOT has been shown to protect injured retinal neurons from programmed cell death (). By enhancing the diffusion of oxygen from the choroid into the deep retina, HBOT could especially help regions suffering poor blood flow (). However, these ideas are theoretical for glaucoma. The typical goal is that extra oxygen might “rescue” stressed ganglion cells. That said, oxygen also reacts in tissues: high oxygen can generate reactive oxygen species (ROS), which can damage cells if overwhelming. Thus, HBOT in the eye is a balance – it may relieve hypoxia, but also carries a risk of oxidative injury () (). Retinal Ganglion Cell Bioenergetics and Hyperoxia Retinal ganglion cells (RGCs) are highly energy-demanding neurons. They rely on their mitochondria to perform oxidative phosphorylation (using oxygen to make ATP). During normal oxygen levels, mitochondria in RGCs generate most of the needed cellular energy. If oxygen is low (hypoxia), cells must switch to less efficient processes (glycolysis) and may starve for energy (). In glaucoma, one factor leading to RGC damage is thought to be poor oxygen supply (due toSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/oxidative-stress-hormesis-and-the-hyperoxia-paradox-in-glaucomaTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Introduction Glaucoma is an eye disease in which damage to the optic nerve leads to gradual vision loss. In glaucoma and other eye disorders, oxidative stress – the build-up of harmful reactive oxygen species (ROS) – has long been implicated in tissue injury (). Oxygen itself, however, plays a dual role in health. Our eyes need oxygen as a vital fuel: the retina has one of the highest oxygen demands in the body, for example, and oxygen is used constantly in nerve-cell metabolism. This is why supplemental oxygen (even in a hyperbaric oxygen therapy (HBOT) setting) can aid healing in some conditions. But paradoxically, too much oxygen can generate excess ROS and cause tissue damage. Under hyperoxic conditions (high oxygen levels), the body produces superoxide, hydrogen peroxide, and other radicals that trigger inflammation and cell injury (). In short, oxygen is life-giving at moderate levels but can be toxic at high doses () (). This “hyperoxia paradox” – oxygen as both medicine and poison – is central to understanding oxidative stress in glaucoma. Oxygen: Medicine and Menace in the Eye Oxygen is indispensable for normal eye function. Retinal cells (especially in the macula and photoreceptor layer) use oxygen to convert nutrients into energy. A steady oxygen supply from the choroid and retinal blood vessels keeps these neurons and support cells alive. In addition, oxygen delivered by blood to the trabecular meshwork (the filtering tissue that helps drain intraocular fluid) and the accommodating lens supports their metabolism. Clinically, supplemental oxygen is sometimes used to improve healing. For example, hyperbaric oxygen therapy (HBOT) – breathing 100% oxygen under pressure – is used for chronic wounds and radiation injury, and it can increase oxygen delivery to eye tissues. However, as medical sources warn, too much oxygen can be harmful (). Hyperoxia disturbs the body’s normal balance and produces a burst of ROS (). “Reactive oxygen species are known problematic by-products of hyperoxia,” notes the medical literature, which explains that excess ROS lead to a cycle of tissue injury, inflammation, and cell death (). In other words, what helps at low doses can hurt at high doses. Free radicals generated by hyperoxia will indiscriminately chemically modify nearby molecules (membranes, DNA, proteins), potentially crippling those cells. For instance, oxygen therapy that is prolonged or at very high pressure can cause oxygen toxicity, affecting sensitive organs. In the eye, this means that while a brief high-oxygen treatment might boost healing or blood flow, it could also spark damaging oxidative stress. Hormesis: Beneficial Stress? The concept of hormesis helps explain how a mild oxidative stress can sometimes be beneficial. Hormesis is a well-known two-phase response in biology: a low or moderate rise in a stressor tends to activate adaptive defenses, whereas very high levels overwhelm those defenses and become toxic (). Oxygen itself is a classic hormetic example: just above-normal oxygen helps cells function, but extreme hyperoxia injures them (). Some experts have even suggested that modest, intermittent bursts of oxygen could precondition tissues and strengthen antioxidant mechanisms. As one science newSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/soccer-and-glaucoma-endurance-gains-amid-collision-risksTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Soccer and Glaucoma: Endurance Gains Amid Collision RisksSoccer is a vigorous team sport that combines aerobic exercise with short bursts of sprinting. For people with glaucoma, the question arises: are the fitness and social benefits of soccer worth the potential eye risks? On one hand, regular running and teamwork can boost cardiovascular health, lower eye pressure, and even slow glaucoma progression. On the other hand, soccer involves collisions, flying balls, and outdoor exposure that can injure the eyes. Below we explore how soccer’s intermittent exercise affects intraocular pressure (IOP), balance those health gains against eye injury hazards (from headers, kicks or weather), and suggest practical ways to play safely. Aerobic Fitness and Team Benefits Playing soccer provides excellent cardiorespiratory exercise. The running, jogging, and game movement substantially raise heart rate and build endurance. Research shows that moderate aerobic exercise can lower intraocular pressure, the key risk factor in glaucoma. For example, a study found that 15 minutes of treadmill running reduced average eye pressure from about 14.9 mmHg to 11.1 mmHg immediately after exercise (). Likewise, a glaucoma foundation article notes that activities like walking, running or swimming “stand out for their ability to significantly lower IOP” (). Over time, keeping IOP lower helps protect the optic nerve from damage.In large population studies, physically fit people developed glaucoma at much lower rates. In one long-term study of nearly 30,000 male runners, better fitness and more exercise were linked to sharply reduced glaucoma risk () (). Runners who could maintain a fast pace (over 5.0 m/s) had virtually no cases of new glaucoma (). In another study of over 9,500 adults, those who met the recommended exercise guidelines (at least 500 MET-minutes/week) had only about half the glaucoma risk of inactive people (). Even having good overall fitness (high cardiorespiratory fitness) cut glaucoma risk by ~40% (). These findings suggest that soccer’s regular endurance exercise – similar to running – can be protective for eye health in the long run.Beyond the raw numbers, soccer also boosts general wellness and team spirit. Playing on a team encourages discipline, social support, and stress relief. Exercise and camaraderie help reduce stress hormones, which may indirectly benefit eye pressure control. Many patients find that the fun and motivation of team sports makes it easier to stick with an exercise routine. In short, for a patient cleared to play, soccer offers the fitness and psychological rewards of a team sport, which can contribute to overall health and potentially slow glaucoma progression () ().Soccer’s Exercise and Eye PressureSoccer involves intermittent exercise: periods of running mingle with walking or resting, plus explosive sprints. How does this affect eye pressure? Studies suggest two relevant patterns:Aerobic running lowers IOP: Continuous or moderate running tends to decrease eye pressure. The treadmill study above () is one example. A larger analysis found that long-distance runners had stable or slightly lower post-exercise IOP (about 15.1 mmHg) compared to their baseline (). In contrast, weightlifters (a static, strain-heavy sport) showed significantSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/hiking-and-glaucoma-terrain-altitude-and-sun-exposureTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Hiking and Glaucoma: Terrain, Altitude, and Sun ExposureHiking can be a great way for people with glaucoma to get exercise and enjoy nature – but it also raises questions about eye pressure, blood flow to the optic nerve, and safety on the trail. In general, moderate aerobic exercise (like brisk walking or hiking) is beneficial: it strengthens heart and lung function, helps control blood pressure, and can improve mood and stress resilience (). In fact, a recent review found that outdoor hiking improves cardiovascular health and also “alleviates stress, improves mood, and enhances mental health” (). Higher overall fitness has even been linked to slower glaucoma progression (). However, hiking also brings challenges: long treks can lead to dehydration, strong sunlight, and difficult footing. Importantly for glaucoma patients, we must consider whether hiking acutely affects intraocular pressure (IOP) or ocular perfusion pressure (OPP) (the pressure that drives blood flow to the optic nerve). Below we review how moderate hiking and altitude changes influence IOP/OPP, weigh the health gains against eye risks like dehydration and UV exposure, and give practical advice on gear and pacing. We conclude with criteria to help decide if a high-altitude hike is safe with glaucoma.Hiking’s Effects on Eye Pressure (IOP) and Eye Blood Flow (OPP)Intraocular pressure (IOP) is the fluid pressure inside the eye; it is the main modifiable risk factor in glaucoma. Ocular perfusion pressure (OPP) is roughly the difference between blood pressure in the eye’s arteries and the IOP – it represents the force driving blood through the optic nerve. Low OPP (for example, if blood pressure drops or IOP rises) can starve the optic nerve of blood, which is bad for glaucoma. What does hiking do? Studies of walking and light endurance exercise in glaucoma patients are reassuring. A 2025 clinical trial of people with primary open-angle glaucoma found that walking at a steady, moderate pace (slow or fast) did not cause a dangerous rise in IOP () (). In other words, heart-pumping walking kept IOP roughly the same as before the walk. There was a modest increase in IOP only when subjects carried heavy weights (like a load), which suggests glaucoma patients should avoid very heavy backpacks () (). By contrast, keeping a not-too-heavy load while hiking was safe. In the same study, ocular perfusion pressure increased moderately after the walk – especially at a brisk pace () – meaning that blood flow to the eye actually improved after exercise. Importantly, those OPP gains dropped back to baseline a few minutes after stopping exercise, indicating the change is temporary. Put simply: light to moderate hiking typically lowers glaucoma risk. The research suggests that endurance-type walks tend to keep IOP steady or even slightly lower it, while OPP goes up somewhat () (). This is likely a good thing, since higher OPP gives the optic nerve more blood supply. In fact, the authors conclude that low-intensity exercise “is a safe strategy to improve fitness level” in glaucoma patients () (). Based on this, many eye doctors encourage glaucoma patients to engage in regular moderate exercise, as long as they avoid extreme strain or heavy loads () (). Of course, every patient is different.Support the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/running-and-jogging-with-glaucoma-balancing-cardiovascular-gains-and-iop-fluctuationsTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Introduction Running and jogging improve cardiovascular health and overall wellness, but people with glaucoma often wonder if pounding the pavement could harm their eyes. Glaucoma is a group of diseases marked by damage to the optic nerve, often linked to higher-than-normal intraocular pressure (IOP). In a healthy range, blood pressure drives fluids through the eye (the ocular perfusion pressure, or OPP). For glaucoma patients, maintaining stable blood pressure and eye pressure is crucial. This article explains what happens to IOP and OPP during moderate-to-vigorous running, highlights exercise benefits for vascular and brain health, and warns about possible downsides (like dehydration or impact shocks). You will also get practical tips on safe running intensity, staying hydrated, and special precautions if you have narrow-angle glaucoma, advanced vision loss, or balance problems. Finally, we’ll give clear guidance on how far and how fast to run, and what warning signs to watch for. How Running Affects Eye Pressure Aerobic exercise (like jogging, running, or brisk walking) has immediate effects on eye pressure. Numerous studies show that IOP falls right after a workout. For example, a controlled trial found that after short-term moderate exercise, average IOP significantly decreased while OPP increased (). Similarly, in healthy and glaucoma eyes alike, 30 minutes of steady treadmill running produced a significant drop in IOP (). In other words, your eye pressure tends to go down once you start moving. ... Continue reading at https://visualfieldtest.com/en/running-and-jogging-with-glaucoma-balancing-cardiovascular-gains-and-iop-fluctuationsSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/road-cycling-and-glaucoma-aerobic-advantage-with-posture-and-safety-considerationsTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Introduction Cycling is a healthy, aerobic activity that can help the whole body – including the eyes – when done right. For people with glaucoma (a condition that damages the optic nerve over time), regular moderate exercise like cycling may lower eye pressure and improve blood flow to the optic nerve. However, road cycling also brings some eye-specific challenges: bending forward on a bike can raise eye pressure, and wind, sun and crashes can hurt the eyes. In this article, we review the science on how cycling affects eye health in glaucoma, and give practical tips on bike fit, gear and routines to stay safe. Cycling, IOP (Eye Pressure), Ocular Blood Flow, and Autonomic Balance Regular aerobic exercise has been shown to lower intraocular pressure (IOP) – the fluid pressure inside the eye – which is the main risk factor that patients can change in glaucoma. For example, a 2022 clinical trial in open-angle glaucoma patients found that after a session of cycling and walking, IOP dropped noticeably and the ocular perfusion pressure (an indicator of blood flow into the eye) increased (). Likewise, a review of exercise in healthy people noted that moderate cycling (15–20 minutes) causes a small but significant IOP decrease (). In plain terms, getting your heart rate up tends to let some eye fluid drain out more easily, easing pressure inside the eye. In the 2022 trial, the researchers reported that “aerobic exercise is beneficial for patients with primary open-angle glaucoma” because of these IOP and blood flow changes (). Exercise also boosts blood flow throughout the body – including the eyes. Improved circulation means more oxygen and nutrients to the optic nerve and retina (the light-sensing tissue): one article notes that aerobic exercise “significantly lower[s] [IOP] and improve[s] blood circulation throughout the body, including the eyes” (). In eye-specific terms, lowering IOP while keeping blood pressure steady raises the driving pressure that pushes blood into the optic nerve (this is ocular perfusion pressure). So after cycling, more blood can reach the optic nerve, which is generally good for eye health. In addition, regular exercise helps the body’s autonomic nervous system (which controls things like heart rate and blood vessel tone) to stay in balance. In a rodent model of glaucoma risk, researchers found that ten weeks of treadmill exercise prevented a diet-induced rise in IOP and also prevented excessive sympathetic (stress) nerve activity (). In other words, exercise training made the animals’ autonomic responses more normal and kept their eye pressure from rising. By analogy, routine aerobic exercise in people helps keep the “fight-or-flight” stress response in check, which may further stabilize eye pressure and blood flow. Key point: Moderate cycling workouts tend to lower IOP and increase ocular blood flow. Regular aerobic conditioning (cycling, walking, swimming, etc.) has been shown to slow the progression of glaucoma. For instance, one study cited by the Glaucoma Research Foundation found that people who do moderate-to-vigorous aerobic exercise at least three times a week had about a 10% slower rate of vision loss than those who did little exercise (). In short, Support the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/snorkeling-and-glaucoma-gentle-aquatic-activity-with-mask-and-sunlight-considerationsTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Snorkeling with Glaucoma: Benefits and CautionsSnorkeling is a popular, low-impact water activity that many people enjoy. For someone with glaucoma—an eye condition often related to high intraocular pressure (IOP) and peripheral vision loss—snorkeling may seem worrisome. In fact, snorkeling involves shallow swimming at the water’s surface, with minimal exertion. This means it generally causes little change in eye pressure (IOP). In contrast, deep scuba diving significantly increases pressure on the body. Research shows that diving masks (like those used for snorkeling) do not raise IOP; in one study, putting on a standard diving mask actually lowered IOP slightly (). By contrast, tight swimming goggles can squeeze around the eyes and temporarily raise IOP (). In practice, wearing a well-fitted snorkel mask (with a nose pocket) tends to spread pressure evenly and is safer for glaucoma than snug swim goggles () (). Importantly, snorkeling is mostly done at the surface where the water pressure is nearly the same as on land, so you avoid the pressure changes of deep diving. As long as you stay at shallow depth, you typically won’t encounter the “mask squeeze” injuries (like bleeding in the eye) that can happen when divers descend without exhaling through the nose to equalize pressure (). So for surface snorkeling, mask pressure effects are minimal.Benefits of Snorkeling as Gentle ExerciseSnorkeling provides light aerobic exercise comparable to swimming, walking, or mild jogging. Exercise has well-known health benefits, and studies suggest it can be good for glaucoma patients too. Regular moderate exercise tends to lower IOP and improve blood flow in the eyes. For example, research finds that people who meet physical activity guidelines have a lower risk of developing glaucoma (), and aerobic workouts (like swimming) can reduce eye pressure and even expand drainage channels in the eyes () (). In practical terms, spending time snorkeling gets your heart rate up without hard impact on the body. Besides physical fitness, snorkeling can be relaxing and mentally refreshing. Being immersed in water and watching underwater life often reduces stress and anxiety, which is healthy for the body and eyes. Studies and expert opinions note that swimming-based activities (like snorkeling) improve mental well-being, releasing tension and boosting mood (). In short, for many glaucoma patients, snorkeling offers a safe, low-pressure workout – it raises the heart rate gently but does not involve straining or inverted poses that spike IOP (). Potential Eye Risks from SnorkelingWhile snorkeling is mild, there are some considerations to keep eyes healthy:Mask Pressure: A snorkeling mask that fits properly should not sharply increase IOP (). Use a diving-style mask that covers both eyes and the nose together (rather than separate swim goggles). These larger masks distribute pressure and include a nose pocket, making it easier to equalize if you dive down. In one study, wearing a diving mask did not raise IOP – in fact, IOP slightly decreased (). By contrast, very tight small swim goggles can raise IOP by about 4–5 mmHg while worn (), although this effect is usually temporary. The bottom line: pick a comfortable masSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/scuba-diving-and-glaucoma-pressure-perfusion-and-post-surgical-precautionsTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Introduction Scuba diving has become a popular recreational sport, but it poses unique challenges for eye health. Divers are exposed to rapid ambient pressure changes underwater, which can influence intraocular pressure (IOP) and blood flow in the eyes. People with glaucoma – a condition where elevated IOP can damage the optic nerve – may worry about the effects of diving. Fortunately, experts report that diving per se hasn’t been shown to worsen glaucoma, likely because diving affects the difference between the pressure inside the eye and the surrounding water, not just the eye’s absolute pressure (). Nonetheless, divers with glaucoma must take precautions. This article reviews how water pressure, mask squeeze, and equalization affect IOP and ocular perfusion, weighs the health benefits of diving against its risks for glaucoma patients, and offers practical guidelines. Every recommendation is grounded in current research and best practices.How Underwater Pressure Affects the Eye Underwater, pressure increases by about one atmosphere every 10 meters (33 feet) of depth. In theory, higher external pressure could compress the eyeball and raise IOP. However, studies generally show the opposite effect: diving or simulated high-pressure environments tend to lower IOP slightly () (). For example, a recent systematic review found that experimental hyperbaric studies often reported reduced IOP under increased pressure (). One trial observed an ~8% drop in IOP measured 30 minutes after a 25-meter dive (); another noted that IOP remained below baseline even during the dive. The reasons are not fully understood, but may include changes in blood flow and oxygenation.Diving also alters ocular perfusion pressure (the difference between arterial blood pressure and IOP). Immersion and cold water trigger peripheral vasoconstriction, which can raise overall blood pressure. This tends to increase ocular perfusion pressure (). In concert, high blood oxygen levels (hyperoxia) cause constriction of retinal and choroidal blood vessels. In fact, one review notes that hyperbaric oxygen often causes ocular vasoconstriction and choroidal thinning, which can further reduce IOP (). In summary, the net effect of diving physiology seems to be a modest decrease in IOP and an increase in perfusion pressure – potentially beneficial for glaucoma if the optic nerve receives more blood flow. Still, the effects may vary and are incompletely understood.Mask Squeeze and Equalization A special concern for divers is the pressure difference between a diver’s mask and the surrounding water. Without equalization, the mask can “suck” on the face and eyes as the pressure increases, a phenomenon known as mask squeeze. To avoid this, divers are trained to equalize the mask by gently exhaling air through the nose into the mask during descent (). This keeps the internal mask pressure nearly equal to the ambient pressure. According to diving experts, skipping equalization can cause serious ocular barotrauma (): the vacuum can pull on the eye and eyelids, leading to bruising (periorbital ecchymosis), lid swelling, and subconjunctival hemorrhages (bleeding under the conjunctiva) (). In severe cases, it can even cause bleeding inside the eye (hyphema) or in the orSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/lap-swimming-and-glaucoma-cardiorespiratory-benefits-vs-goggle-and-head-position-issuesTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Lap Swimming and Glaucoma: Cardiorespiratory Benefits vs. Goggle and Head Position IssuesSwimming is an excellent low-impact, aerobic exercise. For people with glaucoma, staying active is important because regular exercise tends to lower eye pressure and improve blood flow. In fact, studies show that moderate aerobic workouts (like swimming, brisk walking, or cycling) significantly reduce intraocular pressure (IOP) in both healthy eyes and glaucoma patients (). Lowering IOP and improving blood flow to the optic nerve helps protect vision. Swimming also builds heart and lung health with minimal stress on joints, making it a great choice for older adults or those with joint pain (). However, swimming has some unique eye-related factors. Tight-fitting goggles, the face-down posture of freestyle, and chlorinated pool water can affect the eyes. In this article we review the evidence on how lap swimming affects IOP and ocular blood flow. We compare the stroke styles (freestyle, backstroke, breaststroke), weigh the cardio benefits against any risks, and offer practical tips on goggles and technique. For anyone with glaucoma or at risk, the goal is to swim safely and enjoy the health benefits while minimizing eye stress.Aerobic Swimming and Eye PressureSwimming is aerobic exercise, so it shares the general benefits of workouts. Numerous scientific studies report that aerobic exercise lowers eye pressure. For example, a clinical trial found that 30 minutes of moderate treadmill running significantly reduced IOP in primary open-angle glaucoma patients as well as healthy subjects (). The study used advanced imaging to show that exercise actually expanded the eye’s drainage channels and let fluid out more easily, which explains the pressure drop. This effect is temporary (IOP usually returns to baseline after stopping), but regular exercise habitually lowers overall eye pressure. Lower and more stable IOP is a key goal in glaucoma management. In fact, large body of research confirms that both chronic high IOP and frequent pressure spikes are risk factors for glaucoma progression (). So, advocating aerobic exercise like swimming is in line with maintaining healthy eye pressure over time. Swimming also increases heart rate and blood circulation, which generally helps deliver oxygen (and medication) to the eye tissues. Importantly, water exercise is low-impact. The buoyancy of water cancels most weight load, making swimming accessible if you have arthritis or joint issues. An exercise review notes that the resistance of water reduces stress on joints and muscles, so older adults often find pool workouts comfortable (). This ease of movement means people are more likely to stick with swimming long-term. For glaucoma patients or at-risk individuals, staying fit and reducing sedentary lifestyle is vital. In summary, the cardiovascular and metabolic benefits of regular swimming (improved fitness, circulation, mood, etc.) are overwhelmingly positive and can indirectly support eye health.Swimming Goggles and Eye PressureWhile the cardio benefits are clear, swimming has potential eye-specific downsides – notably, wearing tight swimming goggles. Most goggles form an airtight seal around the eye socket. ThiSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/basketball-and-glaucoma-dynamic-cardio-with-contact-and-glare-considerationsTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Introduction Glaucoma is a chronic eye disease in which high intraocular pressure (IOP) or other factors gradually damage the optic nerve, often leading to peripheral vision loss. Patients naturally worry whether vigorous sports like basketball are safe. In fact, moderate exercise is generally healthy – it boosts blood flow and slows vision loss – but basketball’s contact and bright lights pose special challenges. This article examines how basketball affects eye pressure during sprints and jumps, how field loss can make court play risky, and how players with glaucoma can balance the aerobic and social benefits of the game against the risks of injuries and glare. We’ll also offer practical strategies (goggles, modified play, hydration) and guidance on playing basketball according to disease severity, always citing evidence from eye health research and sports safety guidelines. Exercise and Intraocular Pressure Basketball is a dynamic sport combining aerobic running and short explosive movements. Studies of exercise and IOP show that aerobic activities tend to lower eye pressure in both healthy and glaucoma patients. For example, one large study found that after jogging, subjects’ IOP significantly decreased, even in glaucoma patients on medication (). In fact, that study concluded there was “no ocular restriction for simple glaucoma patients in performing aerobic physical activity” (). Similarly, the Glaucoma Research Foundation notes that moderate-to-vigorous exercise (like jogging or biking) improved cardiovascular health and significantly lowered IOP, slowing visual field loss by about 10% over time (). These benefits likely apply to basketball since most of the game (running the court, defense, etc.) is aerobic. ... Continue reading at https://visualfieldtest.com/en/basketball-and-glaucoma-dynamic-cardio-with-contact-and-glare-considerationsSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/general-resistance-training-and-glaucoma-building-strength-while-managing-iop-spikesTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:General Resistance Training and Glaucoma: Building Strength While Managing IOP SpikesIntroduction: Strength training is a proven way to boost fitness, control weight, improve blood sugar and blood pressure, and build muscle and bone – benefits that reduce risk of diabetes, heart disease, and falls in older adults () (). However, for people with glaucoma (a disease caused by damage to the optic nerve, often from high eye pressure), heavy lifting can briefly spike intraocular pressure (IOP) inside the eye. Since high IOP is the main modifiable risk factor for glaucoma progression (), we must find a balance: enjoy the health perks of resistance exercise while keeping IOP under control.Why Strength Training Matters Resistance exercises (like lifting weights or using bands) help maintain metabolic health and strength as we age. Regular strength training lowers body fat and abdominal obesity, improves insulin sensitivity and blood sugar control, and even modestly reduces blood pressure (). This combats features of metabolic syndrome (which raises diabetes and heart disease risk). Strength workouts also fight sarcopenia (age-related muscle loss) and osteoporosis (bone thinning), keeping older adults stronger and more independent () (). Importantly, studies show that stronger muscles and better balance from resistance training dramatically reduce fall risk in seniors (). In short, smart strength training can improve overall health, mood and quality of life while helping prevent fractures.How Lifting Affects Eye Pressure Although exercise often lowers IOP after a workout, heavy or strained lifting can acutely raise IOP. We briefly review key findings: dynamic (moving) versus isometric (static hold) lifts, load intensity, breath-holding, and head position.Heavy vs. Moderate Loads: Multiple studies find that heavier weights cause bigger IOP spikes. For example, one review noted that lifting heavy loads and using multi-joint exercises (like squats or bench press) produced the greatest IOP increases (). In a leg-press study, lifting 95% of one’s max (1RM) caused IOP jumps of ~27 mmHg on average, reaching ~40 mmHg absolute () – well above normal (often ~12–15 mmHg). Even moderate heavy sets (6 reps at 75% 1RM) raised IOP by ~24 mmHg (). By contrast, lighter weights cause smaller spikes. One analysis suggests that using only 20–30% of 1RM (often combined with blood-flow restriction) can still build muscle but with much lower pressure changes (). In practice, choosing moderate weights (e.g. starting around half to two-thirds of your 1RM) and doing more repetitions tends to produce smaller IOP rises than max-effort lifts.Dynamic vs. Isometric Lifting: Both moving exercises and static holds can raise IOP, but their effects may differ. A study comparing three types of leg exercises found that maximal lifts (1 rep at 95% 1RM) and a static isometric push against an immovable load both caused similar large IOP spikes (≈27–29 mmHg increase), whereas multiple reps at 75% (6RM) caused slightly smaller spike (≈24 mmHg) (). In other words, holding a heavy weight still causes dramatic pressure jumps comparable to lifting heavy. Earlier work with bench press showed the same: just lifting a heavy weight caused IOP to risSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/high-intensity-interval-training-hiit-and-glaucoma-short-bouts-big-questionsTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:High-Intensity Interval Training (HIIT) and Glaucoma: Short Bouts, Big QuestionsGlaucoma is a serious eye condition often linked to high intraocular pressure (IOP), the fluid pressure inside the eye (). Managing IOP is key in preventing optic nerve damage. Many patients wonder if lifestyle changes like exercise can help. In fact, physical activity is generally good for eye health – regular aerobic workouts tend to lower IOP and improve blood flow around the optic nerve (). High-Intensity Interval Training (HIIT) is a popular time-efficient workout that boosts heart and metabolic health (). But is HIIT safe for people with glaucoma? We review the evidence on how short bursts of intense activity affect eye pressure. In general, brief high-intensity exercise can reduce IOP over the long run, but very all-out efforts or improper form can cause transient spikes. Understanding the balance of benefits and risks can help glaucoma patients choose the right exercise plan.HIIT and Cardiovascular HealthHIIT involves repeated short bursts of intense exercise (often 80–100% of maximum effort) alternated with brief rest or low-intensity periods (). Because you sweat hard for only a few minutes at a time, HIIT workouts typically take much less time than traditional steady-state cardio. Major health groups note that HIIT can produce the same heart and metabolism benefits as longer workouts but with less total training time (). For example, a review of exercise guidelines found HIIT “consumes less overall time per week” while achieving comparable gains in fitness and cardiometabolic risk factors (). It can improve cholesterol, blood sugar control, and aerobic fitness more quickly than moderate exercise.For busy people, this efficiency is a big plus. A few simple HIIT sessions each week – even two 20-minute routines – can significantly boost cardiovascular health. Switching between fast running, cycling sprints, jump ropes, or bodyweight moves (with short breaks) elevates heart rate and metabolism. Studies in various groups show that HIIT programs can raise VO2max and lower risk factors for diabetes and heart disease, often matching or exceeding steady exercise results (). In short, if time is limited, HIIT offers a powerful workout. However, HIIT’s intensity means it strongly activates the sympathetic nervous system (the “fight or flight” response). This triggers high adrenaline, fast breathing, and surges in blood pressure during each effort. Usually these spikes are short-lived, and healthy vessels quickly adapt. But for glaucoma patients, those transient peaks can cause a sharp but brief rise in IOP. We will review evidence of both the positive long-term eye effects and the potential short-term eye-pressure risks of HIIT.Exercise and Intraocular Pressure: Drops and SpikesOverall, physical activity tends to lower IOP after exercise. Most forms of aerobic work (running, cycling, swimming, brisk walking) produce a modest drop in eye pressure for a few hours afterwards (). The exact mechanism isn’t fully known, but likely factors include faster fluid outflow and improved blood perfusion helping the eye drain aqueous humor. For example, one study found that running a marathon lowered IOP by an average of 2.Support the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/can-eye-blood-vessel-changes-warn-of-future-glaucoma-damage-before-vision-tests-turn-abnormalTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Glaucoma suspects are people who have signs or risk factors for glaucoma but still have normal vision tests. For example, a person might have high eye pressure or a suspicious-looking optic nerve at the back of the eye. Doctors say a glaucoma suspect is someone “with one or more clinical features or risk factors” of future optic nerve damage (). Being a suspect means careful monitoring, not that vision is lost yet.Glaucoma is often called a “silent thief of sight.” It quietly damages the optic nerve before any vision loss shows up. Structural damage means actual changes in the optic nerve or its fibers. Vision loss on a visual field test means those changes have started affecting what you see. In most cases, scans of the eye (like OCT scans) can see nerve thinning before a patient notices any vision change. Experts note that glaucoma damage usually remains asymptomatic until a lot of damage is done (). In fact, many studies find that structural changes in the nerve can be seen years before a visual field test shows problems (). In simple terms, imaging scans can detect early nerve damage before it hurts your eyesight. Microvascular dropout and beta-zone parapapillary atrophy are scan findings eye doctors watch. Microvascular dropout refers to areas where tiny blood vessels around the optic nerve are missing. On special scans called OCT-angiograms (OCTA), these spots look like patches with no blood flow. For instance, researchers describe it as a “complete focal loss of microvasculature” in the tissue around the nerve (). In plain language, imagine there’s a map of blood vessels feeding the nerve, and small sections of that map suddenly have big gaps. Those gaps are microvascular dropout.Beta-zone parapapillary atrophy (beta-zone PPA) is an area of thinning just next to the optic nerve head. The retina there has lost some of its pigment and cells. In doctors’ terms, zone-β PPA is where you can actually see the white sclera (the eye’s “white”) and choroidal blood vessels because the retinal layers are gone (). Put simply, it’s like a bare patch around the nerve where normal retina tissue has worn away. (There is also an “alpha zone” farther out that has irregular pigment, but beta-zone is the inner ring closest to the nerve.) In glaucoma patients, a larger beta-zone often means more nerve damage. The March 17, 2026 study focused on glaucoma suspects and early (preperimetric) glaucoma – people who show early signs on scans but still have normal visual fields. It found that two scan changes may predict future optic nerve damage even before vision tests change. Patients whose scans showed microvascular dropout or an enlarging beta-zone atrophy tended to have optic nerve thinning on later exams. In other words, these eyes were more likely to show structural progression on follow-up. This matches past research: for example, one study found that larger beta-zone PPA at baseline led to faster nerve fiber loss over time (). In the glaucoma-suspect study, eyes with either microvessel dropout or growing beta-zone atrophy had more nerve fiber thinning later on, suggesting these could be early warning markers. Because structural changes often come before symptoms, these findings matter. IfSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/does-angle-closure-risk-build-up-earlier-in-life-than-people-thinkTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:What Is Angle-Closure Glaucoma? Angle-closure glaucoma is a type of glaucoma where the front part of the eye (the drainage angle) becomes blocked. In a healthy eye, a clear fluid called aqueous humor flows through a space called the anterior chamber (behind the cornea and in front of the iris) and drains out through tiny openings. In angle-closure glaucoma, the colored part of the eye (the iris) bulges or moves forward and blocks the drainage angle, so the fluid cannot leave the eye. When fluid builds up, it raises the pressure inside the eye. If this pressure rises suddenly, it can cause severe eye pain, blurred vision, halos around lights, nausea, and even rapidly lead to vision loss. In simple terms, angle-closure glaucoma is like a sink whose drain gets suddenly blocked, causing the “water” (eye fluid) to back up. This needs prompt medical attention . The Anterior Chamber and What “Shallow” Means The anterior chamber is the front part of your eye. It’s the space filled with clear fluid between the cornea (the clear “window” at the very front of the eye) and the iris (the colored ring around the pupil). You can think of it as a small bowl of fluid at the front of the eye (). The depth of this chamber (how deep or shallow it is) is important. A deep chamber means there is plenty of space in front of the iris; a shallow chamber means the iris is closer to the cornea. When the anterior chamber is shallow, the drainage angle at the edge of the chamber can be very narrow. A narrow or shallow chamber can limit fluid flow out of the eye, and research links shallower anterior chambers with a higher risk of glaucoma (). In other words, imagine a shallow bowl versus a deep bowl – in the shallow bowl there is less room for fluid to circulate, making blockage more likely. New Research: How Eye Shape Changes with Age A study published in March 2026 looked at how the anterior chamber changes as people get older. Researchers in Japan measured the anterior chamber depth (ACD) in a large group of adults of different ages. They found that the chamber tends to become shallower (smaller) more quickly in younger adults than expected, and then the change slows down in middle age. In plain language, most of the change in eye shape happens earlier in adulthood rather than steadily getting worse in older age. In fact, in one Japanese health-screening study of over 3,000 people, age was a strong predictor of ACD after accounting for other factors (). This means that by the time many people reach their 40s or 50s, their eyes may have already reached a stable shape. In effect, people who will have narrow angles tend to already have them when they are younger. (By contrast, other studies have shown that overall, ACD does decrease with age (), but the new finding is that much of that decrease may occur earlier than doctors used to think.) In practical terms, it suggests that the risk factors for angle closure may be set up earlier in life. However, it’s important to remember that even if your eyes are a bit narrow when you’re younger, that doesn’t guarantee problems later – it just highlights that any risk might start early. This research is a piece of the puzzle, and it shows doctors how eye anatomy tends to change over time. Why This Matters for EaSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/can-exercise-better-sleep-and-stress-reduction-help-in-glaucoma-what-a-new-march-2026-study-suggestsTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Can Exercise, Better Sleep, and Stress Reduction Help in Glaucoma? What a New March 2026 Study SuggestsGlaucoma is an eye disease where high pressure hurts the optic nerve, causing vision loss. A new report (March 2026) suggests that healthy lifestyle habits might support glaucoma care. It says that exercise, meditation, good sleep, not smoking, and a healthy diet may help keep eyes healthier. However, these are extra supports – they are not a cure and do not replace your doctor’s treatment. Doctors still agree that the only proven way to slow glaucoma is to lower eye pressure with medicine, laser, or surgery () (). Researchers are interested in lifestyle factors because glaucoma involves more than just eye pressure. Things like poor blood flow, stress, or low energy in nerve cells also play a role. Exercise and good nutrition can improve blood flow and nerve health, while stress and smoking can do the opposite. For example, a review in Clinical & Experimental Ophthalmology notes that aerobic exercise and meditation may help protect the optic nerve and slow glaucoma progression () (). In another recent nutrition review, getting more natural nitrates (found in leafy greens) and good sleep were linked to lower glaucoma risk, while smoking and heavy drinking were linked to more eye damage () (). In short, doctors think a healthy body supports healthy eyes.Supporting vs. CuringSupporting eye health: Habits that keep your whole body strong (like exercise and good diet) also help your eyes get better blood flow and nutrients () (). This can make your eyes more resilient. Lowering risk: For people without glaucoma, healthy habits might lower the chance of getting it. For example, studies show people who eat lots of green vegetables (rich in nitrates) have a lower risk of developing glaucoma (). Slowing progression: If you already have glaucoma, these habits might slow how fast it gets worse. In one study, glaucoma patients who walked more each day had slower vision loss over five years (). Another review found that meditation and exercise were linked to slower nerve damage in glaucoma () (). Replacing treatment: Importantly, none of these habits replace your doctor’s treatment. They are added support, not alternatives. No exercise or diet has been proven to cure glaucoma. We still need medicines or surgery to control eye pressure () ().What May Help Overall Eye and Body HealthRegular exercise. Aim for about 30 minutes of moderate aerobic activity most days (brisk walking, swimming, cycling). Exercise improves blood flow and can slightly lower eye pressure () (). It’s good for your heart and eyes. Healthy diet. Eat plenty of vegetables and fruits (especially leafy greens, berries, beans) and lean proteins (fish, poultry). A Mediterranean-style diet or a daily green salad is a good goal. Leafy greens have special nitrates and nutrients linked to better eye blood flow and lower glaucoma risk () (). Avoid too much sugar or processed food. Good sleep. Try to get 7–8 hours of quality sleep every night. Keep a regular sleep schedule. Some studies suggest that poor sleep or sleeping face down can raise eye pressure, while steady breathing and rest help your whole body and Support the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/if-one-person-in-the-family-has-glaucoma-should-everyone-else-get-checkedTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Why family history matters so much in glaucoma Glaucoma is an eye condition that can quietly damage the optic nerve – the nerve that sends vision signals to the brain. Often there are no early symptoms, so people don’t notice any vision loss until late. Because of this, knowing your risk is very important. One big risk factor is family history. In fact, doctors say glaucoma often runs in families. Genetic studies suggest that more than half of glaucoma cases are due to inherited factors (). That means if someone in your close family has glaucoma, your own risk goes up. An eye-care society notes that if a parent, brother, sister, or child (called an immediate family member) has glaucoma, you are about 10 times more likely to get glaucoma yourself ().Importantly, having a family history doesn’t guarantee you will get glaucoma, and not having a family history doesn’t guarantee you won’t. It’s a risk factor, not a certainty. For example, one review found that first-degree relatives of glaucoma patients had an estimated 22% lifetime risk of glaucoma, compared to only about 2% in people without any family history (). In another screening study, about 15% of siblings of glaucoma patients had glaucoma, and 20% of parents did, while only 4% of children (often still young) were diagnosed (). These numbers show higher risk for close relatives, especially siblings and parents, but still a majority of relatives might not have it. Other factors also affect risk – for example, older age or certain ancestries can raise glaucoma risk too (). In short, family history is important because it raises your chances, but it’s one of several factors. What recent research shows about family risk A report published in March 2026 summarized many studies on this topic. That review found that a large fraction of relatives of glaucoma patients show signs of the disease. For example, one study of family members found 8.3% of relatives already had glaucoma and another 19.2% were “glaucoma suspects” (meaning they had early warning signs) (). Altogether, that’s about 27% of relatives with disease or suspected disease. In another clinic study, 13.3% of screened relatives had confirmed glaucoma (). Putting these together, the review concluded that roughly one quarter to one third of close relatives may be affected or at high risk. In practical terms, this means that if you learn a family member has glaucoma, doctors advise that other first-degree relatives – especially siblings – pay attention. The latest research underscores that checking relatives can find many cases early, because one in four or one in three is a much higher count than would be found by chance. Underlying this is the fact that glaucoma has up to 70% heritability (), meaning much of the risk is passed along family lines.Why screening family members is important Glaucoma can slowly steal sight without you noticing. Many people call it a “silent thief of sight.” Surveys estimate nearly half of people with glaucoma don’t know they have it (). The damage is permanent once it occurs, so the key is catching glaucoma early before vision is lost. Early treatment with prescription eye drops, laser or surgery can slow or stop the disease and protect vision (). For Support the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/a-new-glaucoma-drug-study-is-starting-could-an-oral-cannabinoid-help-lower-eye-pressureTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:A New Glaucoma Drug Study Is Starting: Could an Oral Cannabinoid Help Lower Eye Pressure?Some patients may have seen news on March 18, 2026 about a new drug trial for glaucoma and wondered what it means. It’s about a medicine called ART27.13, an experimental oral drug aimed at lowering eye pressure in people with glaucoma or ocular hypertension. In simple terms, this is only a research study. The drug is not FDA-approved or proven to work yet. It is being tested to see if it can safely lower the pressure inside the eye. Before we dive in, let’s remember why eye pressure matters. Glaucoma is a group of eye conditions where high pressure or poor blood flow damages the optic nerve at the back of the eye. That nerve damage causes vision loss. Once vision is lost from glaucoma, it cannot be restored () (). So doctors focus on slowing the damage, not fixing it. The only proven way to slow glaucoma is by lowering the pressure in the eye (). Today this is usually done with eye drops or surgery. A new study is exploring whether ART27.13, an oral drug, can join these treatments. What Is ART27.13?ART27.13 is the code name for a new experimental drug. It is related to cannabinoids – the kinds of active compounds found in the cannabis plant – but it is specially made in a lab. It is taken by mouth (an oral tablet). The reason researchers are interested is that some cannabinoids can lower eye pressure. However, ART27.13 is not just cannabis. It is designed to work mainly outside the brain. In other words, it should not make someone feel high or have the same effects as marijuana. Scientists hope it targets only the eye and body tissues involved in pressure. No one can take ART27.13 outside a doctor’s study right now – it’s only being given to volunteers in the trial. Remember: this is early clinical research. ART27.13 is not an approved medicine yet. It is being studied to see if it is safe and if it can lower eye pressure. We do not know if it will help; that is exactly what the trial is meant to find out. Why Are Cannabinoids of Interest in Glaucoma?Cannabinoids have a long history in glaucoma research. Many people know that marijuana can lower eye pressure a bit (at least for a few hours). In fact, cannabis and related compounds have been known since the 1970s to temporarily reduce intraocular pressure (). Studies show that taking THC or synthetic cannabinoids by mouth can drop pressure by up to about 10–30%, but only for a few hours (). After that, the pressure goes back up. (One review found the maximum drop at 2–4 hours after dose, and it stopped in 3–4 hours () ().) Because of this, some researchers wondered if certain cannabinoids could help with glaucoma. Cannabinoids also have other effects that might help: they can improve blood flow to the optic nerve and may reduce inflammation. But there are problems with using ordinary cannabis. The drop in eye pressure is short-lived and would require dosing many times a day () (). Meanwhile, marijuana causes side effects like feeling “high,” tiredness, and faster heartbeat. Because of that, eye doctors do not use medical cannabis to treat glaucoma. As one eye specialist explained, most glaucoma doctors believe “marijuana is really ineffective” for treSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/what-was-actually-new-in-glaucoma-this-month-a-plain-english-guide-to-the-most-important-march-2026-updatesTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Introduction Glaucoma is a common eye disease that slowly damages the optic nerve and can lead to permanent vision loss. It is usually painless and often unnoticed until vision is already affected. Worldwide, tens of millions of people have glaucoma, making it one of the leading causes of blindness (). Because there is no cure, treatment focuses on slowing or stopping the damage. Almost all current treatments work by lowering eye pressure and require ongoing therapy with eye drops, laser, or surgery. Unfortunately, many patients find daily eye drops hard to use correctly. As one recent review notes, drop therapy often has drawbacks like poor patient adherence (many people forget or fail to use them as prescribed) and side effects () (). This is why scientists and doctors are always looking for better ways to control pressure and protect the optic nerve.In March 2026, several new glaucoma studies and reports drew attention. Some of these findings are already hinting at practical improvements for patients, while others are early-stage research that may only pay off far in the future. This guide will explain the most important updates from the month in plain English: what might help patients soon and what still needs more research (especially distinguishing better diagnosis and monitoring tools versus true treatments or cures). We’ll also flag which headlines deserve caution. What Could Matter to Patients Now New drug-delivery implants (lens/implants for pressure control). One of the biggest practical advances is progress on “sustained-release” implants that deliver glaucoma medicine inside the eye, potentially replacing daily eye drops. For example, an FDA-approved glaucoma implant (bimatoprost intracameral implant, brand name Durysta) can already release a pressure-lowering drug for months after a single insertion (). In March there was news about a related approach: an intraocular lens (IOL) or implant that contains bimatoprost (a common glaucoma drop) and releases it slowly. Although this “BIM-IOL” device still needs more testing, it could eventually be used during cataract surgery so that one procedure also helps control glaucoma pressure without extra drops. These types of long-acting drug devices may arrive in clinics soon. They build on the success of Durysta, and experts note that such sustained-release therapies are an active development area (). Capturing slow changes in eye pressure and fields (monitoring). A recent study (the ADAGES group) looked at long-term glaucoma data and found that changes in eye pressure and vision loss don’t always happen at the same time. In simple terms, your visual field (what you can see on a vision test) often lags behind pressure changes by months or years. This is actually reassuring: it means if your pressure goes up or down a bit, your doctor may have time to notice structural changes (e.g. on scans) before you notice any vision loss. For patients, the takeaway is to trust that doctors will catch worsening disease early with regular tests, even if you feel fine. It emphasizes the monitoring side of care: keep up with check-ups and imaging. (This is mainly a research finding, but iSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/why-is-it-so-hard-to-prove-a-treatment-protects-the-optic-nerve-in-glaucomaTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Introduction When you hear hopeful news about neuroprotection for glaucoma, it’s natural to wonder what that means. In glaucoma, the goal of neuroprotection is to protect the eye’s nerve cells – the ones that carry signals from the eye to the brain – from damage. In other words, neuroprotective treatments aim to keep the optic nerve healthy and alive, not just by lowering eye pressure (the pressure inside the eye, called intraocular pressure), but by directly shielding nerve cells from injury (). As one Cochrane review explains, neuroprotection in glaucoma is any treatment intended to prevent optic nerve damage or cell death (). However, a recent analysis (March 11, 2026) highlights why proving neuroprotection in people is so challenging. The study points out that glaucoma often progresses very slowly and that the usual tests used to measure optic nerve health can be “noisy,” so it’s hard to see clear benefits over a short time. In this article we will explain what neuroprotection means in glaucoma, how it differs from the familiar approach of lowering intraocular pressure, and why this new paper (and others) say neuroprotection trials face big hurdles. We’ll also discuss why many treatments that look promising in the lab fail to become real-world therapies, what kind of evidence doctors need to be convinced a treatment truly protects nerves, and what all this means for patients hoping for more than pressure-lowering therapies.Neuroprotection in Glaucoma: What Does It Mean? Glaucoma is essentially a disease of the optic nerve, where the retinal ganglion cells (the nerve cells in the eye) gradually die off. This death of nerve cells is what causes vision loss in glaucoma (). Right now, all approved glaucoma therapies focus on lowering intraocular pressure, which is the main risk factor for nerve damage. By lowering eye pressure with drops, lasers, or surgery, we can delay glaucoma from getting worse () (). However, even when eye pressure is well controlled, some nerve damage can still happen. That’s why scientists talk about neuroprotection – treatments that go beyond pressure lowering and try to directly save or strengthen the nerve cells.For example, imagine a treatment that boosts the survival of optic nerve fibers or blocks harmful chemical processes in the nerve. If such a treatment were proven to slow down nerve damage, we would call it a neuroprotective therapy. In contrast, a pressure-lowering eye drop does not directly heal or protect the nerve; it simply eases the pressure on it. And “restoring lost vision” is an even bigger leap – that would mean regenerating or replacing the nerve cells and reconnecting them to the brain. Currently, that level of nerve regeneration is largely experimental (ideas like gene therapy or stem cells are being studied) and is not an available treatment () ().To sum up: Lowering eye pressure reduces the mechanical stress that contributes to glaucoma, slowing nerve damage is the job of neuroprotective interventions (if we had them), and restoring lost vision would require repairing or regrowing the damaged nerve, which is still far in the future.Lowering Pressure vs. Protecting Nerves vs. Restoring Vision These three goals – pressure lowering, neuroprotection, and vision reSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/a-new-way-to-read-eye-scans-in-glaucoma-can-3d-nerve-fiber-shape-improve-detectionTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:What Is the Retinal Nerve Fiber Layer (RNFL) and Why It Matters in GlaucomaYour retina at the back of the eye has many layers, including one called the retinal nerve fiber layer (RNFL). This layer is made of long fibers (the axons of retinal ganglion cells) that gather at the optic nerve and carry visual signals to the brain (). In glaucoma, a common eye disease, these nerve cells and their fibers slowly die off. This loss leads to thinning of the RNFL. Doctors rely on finding this thinning as an early sign of glaucoma damage () (). Detecting changes in the RNFL is key because by the time vision loss appears on a field test, about 25–40% of these nerve cells may already be lost () (). In other words, by catching RNFL thinning early, eye doctors hope to treat glaucoma sooner and protect vision.How Doctors Usually Look for Glaucoma on ScansTo check the RNFL, doctors commonly use optical coherence tomography (OCT), a non-invasive imaging test that takes cross-sectional “slice” pictures of the retina. OCT is like an ultrasound for the eye, but it uses light waves to give very detailed images. Most clinical OCT machines take a circular scan around where the optic nerve exits the eye and calculate the RNFL thickness at each point (). This creates a thickness map – it’s often drawn as a double-humped curve (thicker on the top and bottom, thinner on the sides in healthy eyes) (). If glaucoma is present, doctors will see areas where the RNFL is thinner than expected, meaning there are fewer nerve fibers there. In practice, the RNFL thickness measurement from one cross-sectional slice of the OCT is the standard glaucoma parameter ().However, this standard 2D thickness measure has limits. It comes from a single circular scan rather than the whole 3D volume of the scan (). Some scans can be distorted by eye movement or blood vessels, causing artifacts in 20–46% of cases (). Also, in very early glaucoma, thinning might be subtle or patchy and could be missed if one only looks at average thickness values. Researchers have noted that while RNFL thinning is strongly linked to glaucoma, doctors may need to look beyond just simple thickness to improve early detection (). The New 3D Shape-Based Analysis of the RNFLThe 2026 study introduces a new idea: instead of just measuring how thick the RNFL is at a single slice, what if we analyze the whole 3D shape of that nerve fiber layer? Think of it this way: a normal OCT produces a 3D block of data around the optic nerve. Much of that data is not fully used by standard software. The new method, called a registration-based 3D RNFL shape analysis, tries to use more of this information. In simple terms, it lines up the 3D scan images (this is the “registration” part) and looks at the detailed shape of the RNFL surface. It’s like taking a detailed mold of the nerve fiber layer and checking if there are any dents or bumps that indicate damage.Here are the key ideas in patient terms:Full-volume use: Instead of a single circular slice, the method examines every part of the RNFL volume from the OCT scan. This may reveal changes that a single cross-section misses.Shape vs thickness: It doesn’t just report a number for “thickness” at each point. It analyzes the contours and geometrySupport the show